gamma-aminobutyric acid and Pain, Chronic studies

gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.

Research Excerpts

Excerpt	Relevance	Reference
" Gabapentin (a GABA analogue) is efficacious and often well tolerated in other chronic pain conditions."	9.27	GaPP2, a multicentre randomised controlled trial of the efficacy of gabapentin for the management of chronic pelvic pain in women: study protocol. ( Baranowski, A; Bhattacharya, S; Birch, J; Cheong, Y; Cregg, R; Daniels, J; Hewitt, CA; Horne, AW; Macfarlane, GJ; Middleton, L; Szubert, W; Tracey, I; Vincent, K; Williams, ACC, 2018)
" Based on the efficacy of gabapentin in the treatment of chronic pain, we conducted this study to evaluate the efficacy and safety of gabapentin in reducing pain in women with CPP."	9.22	Is gabapentin effective and safe in the treatment of chronic pelvic pain in women: a systematic review and meta-analysis. ( He, Y; Ma, W; Zhuang, X, 2022)
"Gabapentin is prescribed for analgesia in chronic low back pain, yet there are no controlled trials supporting this practice."	9.22	A randomized controlled trial of gabapentin for chronic low back pain with and without a radiating component. ( Abramson, IS; Atkinson, JH; Capparelli, EV; Funk, SD; Gamst, A; Garfin, SR; Matthews, SC; Patel, SM; Rutledge, TR; Slater, MA; Wallace, MS; Wetherell, JL; Wolfson, T; Zisook, S, 2016)
"To identify the clinical action of pregabalin, a proven analgesic, the authors performed three complementary brain neuroimaging procedures: (proton magnetic resonance spectroscopy, functional magnetic resonance imaging, and functional connectivity magnetic resonance imaging) in 17 chronic pain patients diagnosed with fibromyalgia."	9.17	Pregabalin rectifies aberrant brain chemistry, connectivity, and functional response in chronic pain patients. ( Clauw, DJ; Foerster, B; Hampson, J; Harris, RE; Huggins, JP; Kim, J; Napadow, V; Pauer, L; Petrou, M; Schmidt-Wilcke, T; Sundgren, PC, 2013)
"The results of this study suggest that pregabalin works in part by reducing insular glutamatergic activity, leading to a reduction of the increased functional connectivity seen between brain regions in chronic pain states."	9.17	Pregabalin rectifies aberrant brain chemistry, connectivity, and functional response in chronic pain patients. ( Clauw, DJ; Foerster, B; Hampson, J; Harris, RE; Huggins, JP; Kim, J; Napadow, V; Pauer, L; Petrou, M; Schmidt-Wilcke, T; Sundgren, PC, 2013)
"To identify electroencephalographic (EEG) biomarkers for the analgesic effect of pregabalin in patients with chronic visceral pain."	9.16	The analgesic effect of pregabalin in patients with chronic pain is reflected by changes in pharmaco-EEG spectral indices. ( Bouwense, SA; Drewes, AM; Farina, D; Graversen, C; Olesen, AE; Olesen, SS; Steimle, K; van Goor, H; Wilder-Smith, OH, 2012)
"Pregabalin in the doses given decreased morphine requirements for the first 48 h postoperatively, but neither altered the analgesic requirements beyond 48 h nor had any effect on acute, late or chronic pain."	9.16	Perioperative pregabalin for acute and chronic pain after abdominal hysterectomy or myomectomy: a randomised controlled trial. ( Fassoulaki, A; Melemeni, A; Paraskeva, A; Tsaroucha, A, 2012)
"The aim of the present study was to investigate the effect of perioperative administration of pregabalin on postoperative acute and chronic pain and analgesic requirements."	9.16	Perioperative pregabalin for acute and chronic pain after abdominal hysterectomy or myomectomy: a randomised controlled trial. ( Fassoulaki, A; Melemeni, A; Paraskeva, A; Tsaroucha, A, 2012)
"The purpose of this meta-analysis from randomized controlled trials (RCTs) was to determine the efficacy and safety of the preoperative use of gabapentin for the treatment of acute and chronic postoperative pain following breast cancer surgery."	8.98	The efficacy of gabapentin in reducing pain intensity and morphine consumption after breast cancer surgery: A meta-analysis. ( Huang, Q; Jiang, Y; Li, J; Lin, H; Rong, Z; Wang, T; Xiong, J; Zhang, Q; Zhang, S, 2018)
" RCTs comparing gabapentin with placebo in patients undergoing breast cancer surgery were retrieved."	8.98	The efficacy of gabapentin in reducing pain intensity and morphine consumption after breast cancer surgery: A meta-analysis. ( Huang, Q; Jiang, Y; Li, J; Lin, H; Rong, Z; Wang, T; Xiong, J; Zhang, Q; Zhang, S, 2018)
"Preoperative use of gabapentin was able to reduce acute and chronic postoperative pain, total morphine consumption and the occurrence of nausea following breast cancer surgery."	8.98	The efficacy of gabapentin in reducing pain intensity and morphine consumption after breast cancer surgery: A meta-analysis. ( Huang, Q; Jiang, Y; Li, J; Lin, H; Rong, Z; Wang, T; Xiong, J; Zhang, Q; Zhang, S, 2018)
" Meanwhile, oral gabapentin was associated with a reduction of the total morphine consumption after breast cancer surgery."	8.98	The efficacy of gabapentin in reducing pain intensity and morphine consumption after breast cancer surgery: A meta-analysis. ( Huang, Q; Jiang, Y; Li, J; Lin, H; Rong, Z; Wang, T; Xiong, J; Zhang, Q; Zhang, S, 2018)
" We included studies enrolling adult patients undergoing breast cancer surgery who were randomly assigned to preoperative gabapentin or pregabalin versus placebo or active control and assessed acute (≤24 h) or chronic (≥2 months) pain."	8.95	Preoperative pregabalin or gabapentin for acute and chronic postoperative pain among patients undergoing breast cancer surgery: A systematic review and meta-analysis of randomized controlled trials. ( Busse, JW; Choi, S; Clarke, H; Devereaux, PJ; Dhaliwal, J; Khan, JS; Rai, AS, 2017)
"Gabapentin and pregabalin administered perioperatively in patients undergoing breast cancer surgery improve acute postoperative pain as indicated by the reduction in opioid consumption."	8.95	Preoperative pregabalin or gabapentin for acute and chronic postoperative pain among patients undergoing breast cancer surgery: A systematic review and meta-analysis of randomized controlled trials. ( Busse, JW; Choi, S; Clarke, H; Devereaux, PJ; Dhaliwal, J; Khan, JS; Rai, AS, 2017)
"To assess the analgesic efficacy and adverse effects of gabapentin in chronic neuropathic pain and fibromyalgia."	8.90	Gabapentin for chronic neuropathic pain and fibromyalgia in adults. ( Derry, S; Moore, RA; Rice, AS; Toelle, T; Wiffen, PJ, 2014)
"We identified randomised trials of gabapentin for chronic neuropathic pain or fibromyalgia by searching the databases MEDLINE (1966 to March 2014), EMBASE (1980 to 2014 week 10), and CENTRAL in The Cochrane Library (Issue 3 of 12, 2014)."	8.90	Gabapentin for chronic neuropathic pain and fibromyalgia in adults. ( Derry, S; Moore, RA; Rice, AS; Toelle, T; Wiffen, PJ, 2014)
"Randomised, double-blind studies reporting the analgesic and adverse effects of gabapentin in neuropathic pain or fibromyalgia with assessment of pain intensity, pain relief, or both, using validated scales."	8.90	Gabapentin for chronic neuropathic pain and fibromyalgia in adults. ( Derry, S; Moore, RA; Rice, AS; Toelle, T; Wiffen, PJ, 2014)
"The results confirm activity in chronic pain models predicted from affinity for the gabapentin site and suggests, at least partially, that α2δ-subunits of presynaptic voltage-gated calcium channels are involved in mediating this effect."	7.83	Optical isomers of phenibut inhibit [H(3)]-Gabapentin binding in vitro and show activity in animal models of chronic pain. ( Belozertseva, I; Danysz, W; Franke, L; Nagel, J; Valastro, B, 2016)
" Because peripheral nerve lesions are a major cause of chronic pain after surgery, we tested in rats whether analgesic treatment with pregabalin (PGB) has the capacity to mitigate the development of persistent neuropathic pain-like behavior."	7.80	Analgesic treatment with pregabalin does not prevent persistent pain after peripheral nerve injury in the rat. ( Derry, WT; Scholz, J; Vardeh, D; Whang, J; Yang, F, 2014)
"Pregabalin in the context of multimodal pain management may be associated with reduced opioid consumption and other medical complications in patients undergoing TKA, including previous users of chronic pain medications."	7.80	Pregabalin reduces opioid consumption and improves outcome in chronic pain patients undergoing total knee arthroplasty. ( Chen, AF; Hozack, WJ; Parvizi, J; Sawan, H; Viscusi, ER, 2014)
"Orofacial capsaicin and formalin tests were employed in male Wistar rats to assess the influence of pregabalin (or vehicle) pretreatment in acute pain models, and the results from these experiments were analyzed by one-way analysis of variance (ANOVA) followed by Newman Keuls post-hoc test."	7.80	Pregabalin reduces acute inflammatory and persistent pain associated with nerve injury and cancer in rat models of orofacial pain. ( Chichorro, JG; Hummig, W; Kopruszinski, CM, 2014)
"To assess the analgesic effect of pregabalin in orofacial models of acute inflammatory pain and of persistent pain associated with nerve injury and cancer, and so determine its effectiveness in controlling orofacial pains having different underlying mechanisms."	7.80	Pregabalin reduces acute inflammatory and persistent pain associated with nerve injury and cancer in rat models of orofacial pain. ( Chichorro, JG; Hummig, W; Kopruszinski, CM, 2014)
"Pregabalin produced a marked antinociceptive effect in rat models of facial inflammatory pain as well as in facial neuropathic and cancer pain models, suggesting that it may represent an important agent for the clinical control of orofacial pain."	7.80	Pregabalin reduces acute inflammatory and persistent pain associated with nerve injury and cancer in rat models of orofacial pain. ( Chichorro, JG; Hummig, W; Kopruszinski, CM, 2014)
"The secondary outcomes were incidence of chronic pain and complications (the incidence of nausea)."	6.58	The efficacy of gabapentin in reducing pain intensity and morphine consumption after breast cancer surgery: A meta-analysis. ( Huang, Q; Jiang, Y; Li, J; Lin, H; Rong, Z; Wang, T; Xiong, J; Zhang, Q; Zhang, S, 2018)
"Neuropathic pain is more severe, with significant disability."	6.53	Gabapentinoids for chronic low back pain: a protocol for systematic review and meta-analysis of randomised controlled trials. ( AlAmri, R; Bhandari, M; Devereaux, PJ; Gilron, I; Kamath, S; Rajarathinam, M; Shanthanna, H; Thabane, L, 2016)
"Results might vary between different neuropathic pain conditions, and the amount of evidence for gabapentin in neuropathic pain conditions except postherpetic neuralgia and painful diabetic neuropathy, and in fibromyalgia, is very limited."	6.50	Gabapentin for chronic neuropathic pain and fibromyalgia in adults. ( Derry, S; Moore, RA; Rice, AS; Toelle, T; Wiffen, PJ, 2014)
" We are most familiar with the incremental dosing strategy where a ceiling dose is eventually attained guided by efficacy and patient tolerance, after which a fixed dosing regimen is prescribed."	5.91	Comparative Descriptive Analysis of Physician Versus Patient-Directed Gabapentin Usage In Chronic Pain - A Preliminary Report. ( Burns, JC; Gill, JS; Madabhushi, SV; Robinson, CL; Ruan, QZ; Simopoulos, TT, 2023)
" Of the patients still taking gabapentin, 73% were on a fixed schedule, while 27% were on a variable dosing schedule."	5.91	Comparative Descriptive Analysis of Physician Versus Patient-Directed Gabapentin Usage In Chronic Pain - A Preliminary Report. ( Burns, JC; Gill, JS; Madabhushi, SV; Robinson, CL; Ruan, QZ; Simopoulos, TT, 2023)
" None of the patients we surveyed had been given the autonomy to adjust gabapentin doses by their providers and this could significantly reduce the proportion of patients who would be encouraged to run a variable dosing regimen."	5.91	Comparative Descriptive Analysis of Physician Versus Patient-Directed Gabapentin Usage In Chronic Pain - A Preliminary Report. ( Burns, JC; Gill, JS; Madabhushi, SV; Robinson, CL; Ruan, QZ; Simopoulos, TT, 2023)
" Based upon this pilot study, the variable dosing option may be an option for improved therapeutic efficacy or as an alternative to those whose lifestyles do not allow for fixed dosing regimens."	5.91	Comparative Descriptive Analysis of Physician Versus Patient-Directed Gabapentin Usage In Chronic Pain - A Preliminary Report. ( Burns, JC; Gill, JS; Madabhushi, SV; Robinson, CL; Ruan, QZ; Simopoulos, TT, 2023)
"The results confirm activity in chronic pain models predicted from affinity for the gabapentin site and suggests, at least partially, that α2δ-subunits of presynaptic voltage-gated calcium channels are involved in mediating this effect."	5.43	Optical isomers of phenibut inhibit [H(3)]-Gabapentin binding in vitro and show activity in animal models of chronic pain. ( Belozertseva, I; Danysz, W; Franke, L; Nagel, J; Valastro, B, 2016)
"Systemic gabapentin, commonly used to treat chronic pain, impaired the novel object recognition task in normal but not SNL animals."	5.40	Peripheral nerve injury and gabapentin, but not their combination, impair attentional behavior via direct effects on noradrenergic signaling in the brain. ( Eisenach, JC; Hayashida, K; Suto, T, 2014)
"Previous users of chronic pain medications had higher VAS scores but the same opioid consumption compared with those who were not previous users of chronic pain medications."	5.40	Pregabalin reduces opioid consumption and improves outcome in chronic pain patients undergoing total knee arthroplasty. ( Chen, AF; Hozack, WJ; Parvizi, J; Sawan, H; Viscusi, ER, 2014)
" Gabapentin (a GABA analogue) is efficacious and often well tolerated in other chronic pain conditions."	5.27	GaPP2, a multicentre randomised controlled trial of the efficacy of gabapentin for the management of chronic pelvic pain in women: study protocol. ( Baranowski, A; Bhattacharya, S; Birch, J; Cheong, Y; Cregg, R; Daniels, J; Hewitt, CA; Horne, AW; Macfarlane, GJ; Middleton, L; Szubert, W; Tracey, I; Vincent, K; Williams, ACC, 2018)
" Based on the efficacy of gabapentin in the treatment of chronic pain, we conducted this study to evaluate the efficacy and safety of gabapentin in reducing pain in women with CPP."	5.22	Is gabapentin effective and safe in the treatment of chronic pelvic pain in women: a systematic review and meta-analysis. ( He, Y; Ma, W; Zhuang, X, 2022)
"Gabapentin is prescribed for analgesia in chronic low back pain, yet there are no controlled trials supporting this practice."	5.22	A randomized controlled trial of gabapentin for chronic low back pain with and without a radiating component. ( Abramson, IS; Atkinson, JH; Capparelli, EV; Funk, SD; Gamst, A; Garfin, SR; Matthews, SC; Patel, SM; Rutledge, TR; Slater, MA; Wallace, MS; Wetherell, JL; Wolfson, T; Zisook, S, 2016)
"The authors examined the safety and efficacy of intrathecal gabapentin in a randomized, blinded, placebo-controlled, multicenter trial in a heterogeneous cohort of candidates with chronic pain for intrathecal drug therapy."	5.17	Intrathecal gabapentin to treat chronic intractable noncancer pain. ( Coffey, RJ; Grigsby, EJ; McCarville, SE; Page, LM; Rauck, R; Schultz, DM; Wallace, MS; Webster, LR, 2013)
"To identify the clinical action of pregabalin, a proven analgesic, the authors performed three complementary brain neuroimaging procedures: (proton magnetic resonance spectroscopy, functional magnetic resonance imaging, and functional connectivity magnetic resonance imaging) in 17 chronic pain patients diagnosed with fibromyalgia."	5.17	Pregabalin rectifies aberrant brain chemistry, connectivity, and functional response in chronic pain patients. ( Clauw, DJ; Foerster, B; Hampson, J; Harris, RE; Huggins, JP; Kim, J; Napadow, V; Pauer, L; Petrou, M; Schmidt-Wilcke, T; Sundgren, PC, 2013)
"The results of this study suggest that pregabalin works in part by reducing insular glutamatergic activity, leading to a reduction of the increased functional connectivity seen between brain regions in chronic pain states."	5.17	Pregabalin rectifies aberrant brain chemistry, connectivity, and functional response in chronic pain patients. ( Clauw, DJ; Foerster, B; Hampson, J; Harris, RE; Huggins, JP; Kim, J; Napadow, V; Pauer, L; Petrou, M; Schmidt-Wilcke, T; Sundgren, PC, 2013)
"To identify electroencephalographic (EEG) biomarkers for the analgesic effect of pregabalin in patients with chronic visceral pain."	5.16	The analgesic effect of pregabalin in patients with chronic pain is reflected by changes in pharmaco-EEG spectral indices. ( Bouwense, SA; Drewes, AM; Farina, D; Graversen, C; Olesen, AE; Olesen, SS; Steimle, K; van Goor, H; Wilder-Smith, OH, 2012)
"Pregabalin in the doses given decreased morphine requirements for the first 48 h postoperatively, but neither altered the analgesic requirements beyond 48 h nor had any effect on acute, late or chronic pain."	5.16	Perioperative pregabalin for acute and chronic pain after abdominal hysterectomy or myomectomy: a randomised controlled trial. ( Fassoulaki, A; Melemeni, A; Paraskeva, A; Tsaroucha, A, 2012)
"The aim of the present study was to investigate the effect of perioperative administration of pregabalin on postoperative acute and chronic pain and analgesic requirements."	5.16	Perioperative pregabalin for acute and chronic pain after abdominal hysterectomy or myomectomy: a randomised controlled trial. ( Fassoulaki, A; Melemeni, A; Paraskeva, A; Tsaroucha, A, 2012)
"The purpose of this study was to evaluate the analgesic effects of perioperative gabapentin on postoperative acute and chronic pain after coronary artery bypass graft (CABG) surgery with median sternotomy and internal mammary artery harvesting."	5.15	The effects of gabapentin on acute and chronic postoperative pain after coronary artery bypass graft surgery. ( Onan, B; Selcuk, I; Sen, H; Turan, A; Ucak, A; Yilmaz, AT, 2011)
"The purpose of this meta-analysis from randomized controlled trials (RCTs) was to determine the efficacy and safety of the preoperative use of gabapentin for the treatment of acute and chronic postoperative pain following breast cancer surgery."	4.98	The efficacy of gabapentin in reducing pain intensity and morphine consumption after breast cancer surgery: A meta-analysis. ( Huang, Q; Jiang, Y; Li, J; Lin, H; Rong, Z; Wang, T; Xiong, J; Zhang, Q; Zhang, S, 2018)
" RCTs comparing gabapentin with placebo in patients undergoing breast cancer surgery were retrieved."	4.98	The efficacy of gabapentin in reducing pain intensity and morphine consumption after breast cancer surgery: A meta-analysis. ( Huang, Q; Jiang, Y; Li, J; Lin, H; Rong, Z; Wang, T; Xiong, J; Zhang, Q; Zhang, S, 2018)
"Preoperative use of gabapentin was able to reduce acute and chronic postoperative pain, total morphine consumption and the occurrence of nausea following breast cancer surgery."	4.98	The efficacy of gabapentin in reducing pain intensity and morphine consumption after breast cancer surgery: A meta-analysis. ( Huang, Q; Jiang, Y; Li, J; Lin, H; Rong, Z; Wang, T; Xiong, J; Zhang, Q; Zhang, S, 2018)
" Meanwhile, oral gabapentin was associated with a reduction of the total morphine consumption after breast cancer surgery."	4.98	The efficacy of gabapentin in reducing pain intensity and morphine consumption after breast cancer surgery: A meta-analysis. ( Huang, Q; Jiang, Y; Li, J; Lin, H; Rong, Z; Wang, T; Xiong, J; Zhang, Q; Zhang, S, 2018)
" Most studies used oral gabapentin or gabapentin encarbil at doses of 1200 mg or more daily in different neuropathic pain conditions, predominantly postherpetic neuralgia and painful diabetic neuropathy."	4.95	Gabapentin for chronic neuropathic pain in adults. ( Bell, RF; Derry, S; Moore, RA; Phillips, T; Rice, AS; Tölle, TR; Wiffen, PJ, 2017)
"Gabapentin at doses of 1800 mg to 3600 mg daily (1200 mg to 3600 mg gabapentin encarbil) can provide good levels of pain relief to some people with postherpetic neuralgia and peripheral diabetic neuropathy."	4.95	Gabapentin for chronic neuropathic pain in adults. ( Bell, RF; Derry, S; Moore, RA; Phillips, T; Rice, AS; Tölle, TR; Wiffen, PJ, 2017)
" We included studies enrolling adult patients undergoing breast cancer surgery who were randomly assigned to preoperative gabapentin or pregabalin versus placebo or active control and assessed acute (≤24 h) or chronic (≥2 months) pain."	4.95	Preoperative pregabalin or gabapentin for acute and chronic postoperative pain among patients undergoing breast cancer surgery: A systematic review and meta-analysis of randomized controlled trials. ( Busse, JW; Choi, S; Clarke, H; Devereaux, PJ; Dhaliwal, J; Khan, JS; Rai, AS, 2017)
"Gabapentin and pregabalin administered perioperatively in patients undergoing breast cancer surgery improve acute postoperative pain as indicated by the reduction in opioid consumption."	4.95	Preoperative pregabalin or gabapentin for acute and chronic postoperative pain among patients undergoing breast cancer surgery: A systematic review and meta-analysis of randomized controlled trials. ( Busse, JW; Choi, S; Clarke, H; Devereaux, PJ; Dhaliwal, J; Khan, JS; Rai, AS, 2017)
"We know from adult randomised controlled trials that some antiepileptics, such as gabapentin and pregabalin, can be effective in certain chronic pain conditions."	4.95	Antiepileptic drugs for chronic non-cancer pain in children and adolescents. ( Clinch, J; Cooper, TE; Heathcote, LC; Howard, R; Krane, E; Lord, SM; Schechter, N; Sethna, N; Wiffen, PJ; Wood, C, 2017)
"To assess the analgesic efficacy and adverse effects of gabapentin in chronic neuropathic pain and fibromyalgia."	4.90	Gabapentin for chronic neuropathic pain and fibromyalgia in adults. ( Derry, S; Moore, RA; Rice, AS; Toelle, T; Wiffen, PJ, 2014)
"We identified randomised trials of gabapentin for chronic neuropathic pain or fibromyalgia by searching the databases MEDLINE (1966 to March 2014), EMBASE (1980 to 2014 week 10), and CENTRAL in The Cochrane Library (Issue 3 of 12, 2014)."	4.90	Gabapentin for chronic neuropathic pain and fibromyalgia in adults. ( Derry, S; Moore, RA; Rice, AS; Toelle, T; Wiffen, PJ, 2014)
"Randomised, double-blind studies reporting the analgesic and adverse effects of gabapentin in neuropathic pain or fibromyalgia with assessment of pain intensity, pain relief, or both, using validated scales."	4.90	Gabapentin for chronic neuropathic pain and fibromyalgia in adults. ( Derry, S; Moore, RA; Rice, AS; Toelle, T; Wiffen, PJ, 2014)
"In well-established spared nerve injury (SNI)-induced chronic pain-related depression models, the expression of DNMTs and the functional roles and underlying mechanisms of DNMT1 in central amygdala (CeA) GABAergic (gamma-aminobutyric acidergic) neurons were investigated using molecular, pharmacological, electrophysiological, optogenetic, and chemogenetic techniques and behavioral tests."	4.31	DNMT1 Mediates Chronic Pain-Related Depression by Inhibiting GABAergic Neuronal Activation in the Central Amygdala. ( Chen, C; Ding, X; Lin, Y; Liu, Q; Wu, Y; Yan, B; Zheng, H; Zhou, C, 2023)
"The results confirm activity in chronic pain models predicted from affinity for the gabapentin site and suggests, at least partially, that α2δ-subunits of presynaptic voltage-gated calcium channels are involved in mediating this effect."	3.83	Optical isomers of phenibut inhibit [H(3)]-Gabapentin binding in vitro and show activity in animal models of chronic pain. ( Belozertseva, I; Danysz, W; Franke, L; Nagel, J; Valastro, B, 2016)
" For immediate pain relief, intranasal fentanyl worked best and gabapentin was successfully used for chronic pain."	3.83	Newborn with severe epidermolysis bullosa: to treat or not to treat? ( Boesen, ML; Bygum, A; Hertz, JM; Zachariassen, G, 2016)
" Because peripheral nerve lesions are a major cause of chronic pain after surgery, we tested in rats whether analgesic treatment with pregabalin (PGB) has the capacity to mitigate the development of persistent neuropathic pain-like behavior."	3.80	Analgesic treatment with pregabalin does not prevent persistent pain after peripheral nerve injury in the rat. ( Derry, WT; Scholz, J; Vardeh, D; Whang, J; Yang, F, 2014)
"Pregabalin in the context of multimodal pain management may be associated with reduced opioid consumption and other medical complications in patients undergoing TKA, including previous users of chronic pain medications."	3.80	Pregabalin reduces opioid consumption and improves outcome in chronic pain patients undergoing total knee arthroplasty. ( Chen, AF; Hozack, WJ; Parvizi, J; Sawan, H; Viscusi, ER, 2014)
"Orofacial capsaicin and formalin tests were employed in male Wistar rats to assess the influence of pregabalin (or vehicle) pretreatment in acute pain models, and the results from these experiments were analyzed by one-way analysis of variance (ANOVA) followed by Newman Keuls post-hoc test."	3.80	Pregabalin reduces acute inflammatory and persistent pain associated with nerve injury and cancer in rat models of orofacial pain. ( Chichorro, JG; Hummig, W; Kopruszinski, CM, 2014)
"To assess the analgesic effect of pregabalin in orofacial models of acute inflammatory pain and of persistent pain associated with nerve injury and cancer, and so determine its effectiveness in controlling orofacial pains having different underlying mechanisms."	3.80	Pregabalin reduces acute inflammatory and persistent pain associated with nerve injury and cancer in rat models of orofacial pain. ( Chichorro, JG; Hummig, W; Kopruszinski, CM, 2014)
"Pregabalin produced a marked antinociceptive effect in rat models of facial inflammatory pain as well as in facial neuropathic and cancer pain models, suggesting that it may represent an important agent for the clinical control of orofacial pain."	3.80	Pregabalin reduces acute inflammatory and persistent pain associated with nerve injury and cancer in rat models of orofacial pain. ( Chichorro, JG; Hummig, W; Kopruszinski, CM, 2014)
"Gabapentin has been widely used in human medicine to control acute and chronic pain."	3.79	Long-term use of gabapentin for musculoskeletal disease and trauma in three cats. ( Comerford, EJ; Iff, I; Lorenz, ND, 2013)
"The study showed that gabapentin can significantly prevented opioid-induced hyperalgesia (OIH) induced caused by fentanyl and morphine, suggesting a role for the addition of gabapentin in the perioperative period and during chronic pain treatment as an effective drug to prevent OIH."	3.78	Role of gabapentin in preventing fentanyl- and morphine-withdrawal-induced hyperalgesia in rats. ( Wei, W; Wei, X, 2012)
"Phantom limb pain is a debilitating condition for which no effective treatment has been found."	2.82	Phantom motor execution facilitated by machine learning and augmented reality as treatment for phantom limb pain: a single group, clinical trial in patients with chronic intractable phantom limb pain. ( Burger, H; Caine-Winterberger, K; Eriksson, K; Guðmundsdóttir, RA; Hermansson, L; Kristoffersen, MB; Kulbacka-Ortiz, K; Ortiz-Catalan, M; Pihlar, Z; Ragnö, C; Stockselius, A; Widehammar, C; Zepeda-Echavarria, A, 2016)
"The assessment of postoperative pain at the 1- and 3-month follow-ups was performed using a numeric rating scale."	2.76	The effects of gabapentin on acute and chronic postoperative pain after coronary artery bypass graft surgery. ( Onan, B; Selcuk, I; Sen, H; Turan, A; Ucak, A; Yilmaz, AT, 2011)
"A proposed mechanism of chronic pain is dysregulation between the main inhibitory (GABA) and excitatory (glutamate) neurometabolites of the central nervous system."	2.66	Brain GABA and glutamate levels across pain conditions: A systematic literature review and meta-analysis of 1H-MRS studies using the MRS-Q quality assessment tool. ( Aguila, MR; Leaver, AM; Peek, AL; Puts, NA; Rebbeck, T; Watson, J, 2020)
"Chronic pain is long-lasting nociceptive state, impairing the patient's quality of life."	2.66	Viral Vector-Mediated Gene Transfer of Glutamic Acid Decarboxylase for Chronic Pain Treatment: A Literature Review. ( Hao, S; Kanao-Kanda, M; Kanda, H; Liu, S; Roy, S; Toborek, M, 2020)
"The secondary outcomes were incidence of chronic pain and complications (the incidence of nausea)."	2.58	The efficacy of gabapentin in reducing pain intensity and morphine consumption after breast cancer surgery: A meta-analysis. ( Huang, Q; Jiang, Y; Li, J; Lin, H; Rong, Z; Wang, T; Xiong, J; Zhang, Q; Zhang, S, 2018)
"Gabapentin is commonly used to treat neuropathic pain (pain due to nerve damage)."	2.55	Gabapentin for chronic neuropathic pain in adults. ( Bell, RF; Derry, S; Moore, RA; Phillips, T; Rice, AS; Tölle, TR; Wiffen, PJ, 2017)
"Evidence for other types of neuropathic pain is very limited."	2.55	Gabapentin for chronic neuropathic pain in adults. ( Bell, RF; Derry, S; Moore, RA; Phillips, T; Rice, AS; Tölle, TR; Wiffen, PJ, 2017)
"Chronic orofacial pain can greatly improve following treatment of the underlying insomnia, and therefore, re-evaluation of COFP is advised after 1 month of treatment."	2.55	An update of management of insomnia in patients with chronic orofacial pain. ( Almoznino, G; Benoliel, R; Haviv, Y; Sharav, Y, 2017)
"Behavioral therapies for insomnia include the following: sleep hygiene, cognitive behavioral therapy for insomnia, multicomponent behavioral therapy or brief behavioral therapy for insomnia, relaxation strategies, stimulus control, and sleep restriction."	2.55	An update of management of insomnia in patients with chronic orofacial pain. ( Almoznino, G; Benoliel, R; Haviv, Y; Sharav, Y, 2017)
"Chronic postoperative pain is common."	2.53	Preventing chronic postoperative pain. ( Reddi, D, 2016)
"Nerve injury and inflammation promote chronic pain, the risk of which is influenced by patient factors, including psychological characteristics."	2.53	Preventing chronic postoperative pain. ( Reddi, D, 2016)
"The comorbidity of chronic pain and psychiatric disorders, which is well recognized, suggests that the effective therapeutic relief for neuropathic pain induced by SCI can be achieved in conjunction with the management of the sensory and psychiatric aspects of patient."	2.53	Combined approaches for the relief of spinal cord injury-induced neuropathic pain. ( Gwak, YS; Kim, HY; Lee, BH; Yang, CH, 2016)
"Neuropathic pain is more severe, with significant disability."	2.53	Gabapentinoids for chronic low back pain: a protocol for systematic review and meta-analysis of randomised controlled trials. ( AlAmri, R; Bhandari, M; Devereaux, PJ; Gilron, I; Kamath, S; Rajarathinam, M; Shanthanna, H; Thabane, L, 2016)
" There were no significant differences in acute pain outcomes with pregabalin 100-300 mg between single preoperative dosing regimens and those including additional doses repeated after surgery."	2.52	Impact of pregabalin on acute and persistent postoperative pain: a systematic review and meta-analysis. ( Habib, AS; Mishriky, BM; Waldron, NH, 2015)
"Chronic pelvic pain is a common and debilitating condition; its aetiology is multifactorial, involving social, psychological and biological factors."	2.50	Non-surgical interventions for the management of chronic pelvic pain. ( Cheong, YC; Smotra, G; Williams, AC, 2014)
"Results might vary between different neuropathic pain conditions, and the amount of evidence for gabapentin in neuropathic pain conditions except postherpetic neuralgia and painful diabetic neuropathy, and in fibromyalgia, is very limited."	2.50	Gabapentin for chronic neuropathic pain and fibromyalgia in adults. ( Derry, S; Moore, RA; Rice, AS; Toelle, T; Wiffen, PJ, 2014)
"Recent awareness that chronic pain may occur after childbirth has prompted clinicians and researchers to investigate this topic."	2.49	Chronic pain after childbirth. ( Bollag, L; Landau, R; Ortner, C, 2013)
"Chronic pain affects quality of life and adversely affects functional outcomes."	2.49	Management of chronic pain following nerve injuries/CRPS type II. ( Carroll, I; Curtin, CM, 2013)
"There is much information on chronic pain and its treatment, but it is often published outside of surgery and diffusion of this information across disciplines is slow."	2.49	Management of chronic pain following nerve injuries/CRPS type II. ( Carroll, I; Curtin, CM, 2013)
"Chronic neuropathic pain can significantly reduce quality of life and place an economic burden on individuals and society."	2.48	Spinal cord stimulation: neurophysiological and neurochemical mechanisms of action. ( Guan, Y, 2012)
"Not many studies in chronic pain have used (1)H-MRS."	2.48	Imaging central neurochemical alterations in chronic pain with proton magnetic resonance spectroscopy. ( Clauw, DJ; Harris, RE, 2012)
"But its application to chronic pain is relatively new."	2.48	Imaging central neurochemical alterations in chronic pain with proton magnetic resonance spectroscopy. ( Clauw, DJ; Harris, RE, 2012)
"Anxiety and chronic pain are common comorbidities in patients with chronic obstructive pulmonary disease (COPD), which are frequently managed with benzodiazepines (BZDs) and opioids, respectively."	1.91	Co-prescribing of Central Nervous System-Active Medications for COPD Patients: Impact on Emergency Room Visits and Hospitalization. ( Kuo, YF; Raji, MA; Sharma, G; Sood, A; Westra, J, 2023)
" We are most familiar with the incremental dosing strategy where a ceiling dose is eventually attained guided by efficacy and patient tolerance, after which a fixed dosing regimen is prescribed."	1.91	Comparative Descriptive Analysis of Physician Versus Patient-Directed Gabapentin Usage In Chronic Pain - A Preliminary Report. ( Burns, JC; Gill, JS; Madabhushi, SV; Robinson, CL; Ruan, QZ; Simopoulos, TT, 2023)
" Of the patients still taking gabapentin, 73% were on a fixed schedule, while 27% were on a variable dosing schedule."	1.91	Comparative Descriptive Analysis of Physician Versus Patient-Directed Gabapentin Usage In Chronic Pain - A Preliminary Report. ( Burns, JC; Gill, JS; Madabhushi, SV; Robinson, CL; Ruan, QZ; Simopoulos, TT, 2023)
" None of the patients we surveyed had been given the autonomy to adjust gabapentin doses by their providers and this could significantly reduce the proportion of patients who would be encouraged to run a variable dosing regimen."	1.91	Comparative Descriptive Analysis of Physician Versus Patient-Directed Gabapentin Usage In Chronic Pain - A Preliminary Report. ( Burns, JC; Gill, JS; Madabhushi, SV; Robinson, CL; Ruan, QZ; Simopoulos, TT, 2023)
" Based upon this pilot study, the variable dosing option may be an option for improved therapeutic efficacy or as an alternative to those whose lifestyles do not allow for fixed dosing regimens."	1.91	Comparative Descriptive Analysis of Physician Versus Patient-Directed Gabapentin Usage In Chronic Pain - A Preliminary Report. ( Burns, JC; Gill, JS; Madabhushi, SV; Robinson, CL; Ruan, QZ; Simopoulos, TT, 2023)
"Development of chronic pain has been attributed to dysfunctional GABA signaling in the spinal cord."	1.72	Analgesic effect of recombinant GABAergic precursors releasing ω-conotoxin MVIIA in a model of peripheral nerve injury in rats. ( Hernandez, M; Jergova, S; Sagen, J, 2022)
"Treatment outcomes for migraine and other chronic headache and pain conditions typically demonstrate modest results."	1.62	Increased GABA+ in People With Migraine, Headache, and Pain Conditions- A Potential Marker of Pain. ( Aguila, MR; Foster, S; Galloway, G; Leaver, AM; Ng, K; Oeltzschner, G; Peek, AL; Puts, NA; Rebbeck, T; Refshauge, K; Sterling, M, 2021)
"In particular, chronic pain is associated with altered medial prefrontal anatomy and biochemistry."	1.62	Disruption to normal excitatory and inhibitory function within the medial prefrontal cortex in people with chronic pain. ( Alam, M; Gustin, SM; Hesam-Shariati, N; Kang, D; McAuley, JH; Rae, CD; Trost, Z, 2021)
"Chronic pain is pain greater than 3 months duration that may result from disease, trauma, surgery, or unknown origin."	1.51	Magnetic resonance spectroscopy across chronic pain disorders: a systematic review protocol synthesising anatomical and metabolite findings in chronic pain patients. ( Barry, D; Drago, T; Gallagher, H; King, R; Levins, KJ; Martin, A; Murphy, P; O'Hanlon, E; Roddy, DW; Roman, E, 2019)
"Cyclobenzaprine specimens were equally likely to be positive whether the dose was oral or topical, although mean levels after topical dosing were approximately 13-21% those after oral dosing."	1.46	Urinary Concentrations of Topically Administered Pain Medications. ( Bell, P; Glinn, MA; Harvey, A; Lickteig, AJ; Rappold, B; Recer, S; Salske, M; Stensland, J; Weber, L, 2017)
" Cyclobenzaprine specimens were equally likely to be positive whether the dose was oral or topical, although mean levels after topical dosing were approximately 13-21% those after oral dosing."	1.46	Urinary Concentrations of Topically Administered Pain Medications. ( Bell, P; Glinn, MA; Harvey, A; Lickteig, AJ; Rappold, B; Recer, S; Salske, M; Stensland, J; Weber, L, 2017)
"A common treatment for chronic pain is prescription of analgesics, but their long-term use entails risk of morbidity, addiction and misuse."	1.46	Urinary Concentrations of Topically Administered Pain Medications. ( Bell, P; Glinn, MA; Harvey, A; Lickteig, AJ; Rappold, B; Recer, S; Salske, M; Stensland, J; Weber, L, 2017)
"Compared with nociceptive pain, neuropathic pain is a challenging diagnosis to make and successfully treat in children with cancer."	1.46	Very-Low-Dose Methadone To Treat Refractory Neuropathic Pain in Children with Cancer. ( Bruera, E; Madden, K, 2017)
"Pyridoxine-sensitive seizures characterize severe forms of infantile HPP."	1.46	Neuromuscular features of hypophosphatasia. ( Fonta, C; Salles, JP, 2017)
" This study underscores our previous findings that eToims is safe and efficacious for long-term use in CRMP."	1.43	Chronic refractory myofascial pain and denervation supersensitivity as global public health disease. ( Bruyninckx, F; Chu, J; Neuhauser, DV, 2016)
"Low back pain has a 9."	1.43	Chronic refractory myofascial pain and denervation supersensitivity as global public health disease. ( Bruyninckx, F; Chu, J; Neuhauser, DV, 2016)
"The results confirm activity in chronic pain models predicted from affinity for the gabapentin site and suggests, at least partially, that α2δ-subunits of presynaptic voltage-gated calcium channels are involved in mediating this effect."	1.43	Optical isomers of phenibut inhibit [H(3)]-Gabapentin binding in vitro and show activity in animal models of chronic pain. ( Belozertseva, I; Danysz, W; Franke, L; Nagel, J; Valastro, B, 2016)
"Chronic postsurgical pain (CPSP) is a common problem, with up to a third of patients reporting persistent or intermittent pain 1 year after common operations."	1.40	Chronic postsurgical pain: prevention and management. ( Ravindran, D, 2014)
" The objective of the present study was to evaluate the efficacy and safety of OROS® hydromorphone combined with pregabalin in patients with chronic non-cancer neuropathic pain."	1.40	Long-term efficacy of OROS® hydromorphone combined with pregabalin for chronic non-cancer neuropathic pain. ( Casali, M; Dauri, M; Lazzari, M; Sabato, AF; Sabato, E; Tufaro, G, 2014)
" Dosage and side effects were recorded at each visit."	1.40	Long-term efficacy of OROS® hydromorphone combined with pregabalin for chronic non-cancer neuropathic pain. ( Casali, M; Dauri, M; Lazzari, M; Sabato, AF; Sabato, E; Tufaro, G, 2014)
" Initial mean dosage was 6."	1.40	Long-term efficacy of OROS® hydromorphone combined with pregabalin for chronic non-cancer neuropathic pain. ( Casali, M; Dauri, M; Lazzari, M; Sabato, AF; Sabato, E; Tufaro, G, 2014)
"Treatment for chronic non-cancer neuropathic pain can be complicated by side effects and drug interactions."	1.40	Long-term efficacy of OROS® hydromorphone combined with pregabalin for chronic non-cancer neuropathic pain. ( Casali, M; Dauri, M; Lazzari, M; Sabato, AF; Sabato, E; Tufaro, G, 2014)
"Seventeen percent (n = 224) had purely neuropathic pain."	1.40	Long-term efficacy of OROS® hydromorphone combined with pregabalin for chronic non-cancer neuropathic pain. ( Casali, M; Dauri, M; Lazzari, M; Sabato, AF; Sabato, E; Tufaro, G, 2014)
"In this study, on a rat model of chronic pain, we determined how persistent pain altered behavioral responses to morphine reward measured by the paradigm of unbiased conditioned place preference (CPP), focusing on GABAergic synaptic activity in neurons of the central nucleus of the amygdala (CeA), an important brain region for emotional processing of both pain and reward."	1.40	Persistent pain facilitates response to morphine reward by downregulation of central amygdala GABAergic function. ( Hou, YY; Lu, YG; Pan, ZZ; Tao, W; Wang, W; Zhang, Z, 2014)
"Systemic gabapentin, commonly used to treat chronic pain, impaired the novel object recognition task in normal but not SNL animals."	1.40	Peripheral nerve injury and gabapentin, but not their combination, impair attentional behavior via direct effects on noradrenergic signaling in the brain. ( Eisenach, JC; Hayashida, K; Suto, T, 2014)
"Previous users of chronic pain medications had higher VAS scores but the same opioid consumption compared with those who were not previous users of chronic pain medications."	1.40	Pregabalin reduces opioid consumption and improves outcome in chronic pain patients undergoing total knee arthroplasty. ( Chen, AF; Hozack, WJ; Parvizi, J; Sawan, H; Viscusi, ER, 2014)
"Neuropathic pain is currently an insufficiently treated clinical condition."	1.40	Soluble epoxide hydrolase inhibition is antinociceptive in a mouse model of diabetic neuropathy. ( Hammock, BD; Inceoglu, B; Wagner, K; Yang, J, 2014)
"Gabapentin has been widely used in human medicine to control acute and chronic pain."	1.39	Long-term use of gabapentin for musculoskeletal disease and trauma in three cats. ( Comerford, EJ; Iff, I; Lorenz, ND, 2013)
" This report details the long-term use of gabapentin for musculoskeletal pain or head trauma in three cats."	1.39	Long-term use of gabapentin for musculoskeletal disease and trauma in three cats. ( Comerford, EJ; Iff, I; Lorenz, ND, 2013)
"Managing chronic pain, particularly in the feline patient, poses a challenge to veterinary surgeons."	1.39	Long-term use of gabapentin for musculoskeletal disease and trauma in three cats. ( Comerford, EJ; Iff, I; Lorenz, ND, 2013)
"To induce hyperalgesia, Sprague Dawley (SD) rats were subcutaneously injected with fentanyl four times at 15-min intervals (60 μg/kg per injection), resulting in total dose of 240 μg/kg over 1 h, and morphine 10 mg/kg twice daily for 7 days."	1.38	Role of gabapentin in preventing fentanyl- and morphine-withdrawal-induced hyperalgesia in rats. ( Wei, W; Wei, X, 2012)
"Depression, epilepsy, post traumatic stress disorder (PTSD), and chronic pain exemplify medical conditions that are exacerbated by stress, have low heart rate variability (HRV) and low GABAergic activity, respond to pharmacologic agents that increase activity of the GABA system, and show symptom improvement in response to yoga-based interventions."	1.38	Effects of yoga on the autonomic nervous system, gamma-aminobutyric-acid, and allostasis in epilepsy, depression, and post-traumatic stress disorder. ( Brown, RP; Ciraulo, DA; Gerbarg, PL; Saper, RB; Streeter, CC, 2012)

Research

Studies (108)

Authors

Clinical Trials (29)

Trial Overview

Trial Outcomes

"VAS Score 1: How Much Pain do You Feel in Your Operative Site When Resting?"

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	92 (85.19)	24.3611
2020's	16 (14.81)	2.80

Authors	Studies
He, Y	1
Zhuang, X	1
Ma, W	1
Baumbach, P	1
Meißner, W	1
Reichenbach, JR	1
Gussew, A	1
Sood, A	1
Kuo, YF	1
Westra, J	1
Sharma, G	1
Raji, MA	1
Jergova, S	1
Hernandez, M	1
Sagen, J	1
Pigott, T	1
McPeak, A	1
de Chastelain, A	1
DeMayo, MM	1
Rasic, N	1
Rayner, L	1
Noel, M	1
Miller, JV	1
Harris, AD	1
Ding, X	1
Lin, Y	1
Chen, C	1
Yan, B	1
Liu, Q	1
Zheng, H	1
Wu, Y	1
Zhou, C	1
Li, X	2
Zhu, Y	2
Sun, H	2
Shen, Z	2
Sun, J	2
Xiao, S	2
He, X	2
Liu, B	2
Wang, Y	3
Hu, Y	1
Liang, Y	1
Jiang, Y	2
Du, J	2
Xu, C	2
Fang, J	2
Shao, X	2
Zhu, X	1
Yao, PA	1
Zhang, C	3
Yu, W	1
Wu, Z	1
Ruan, QZ	1
Robinson, CL	1
Simopoulos, TT	1
Burns, JC	1
Madabhushi, SV	1
Gill, JS	1
Awad-Igbaria, Y	1
Abu-Ata, S	1
Nakhleh-Francis, Y	1
Lowenstein, L	1
Ginat, K	1
Bornstein, J	1
Palzur, E	1
Shamir, A	1
Levins, KJ	1
Drago, T	1
Roman, E	1
Martin, A	1
King, R	1
Murphy, P	1
Gallagher, H	1
Barry, D	1
O'Hanlon, E	1
Roddy, DW	1
Peek, AL	2
Rebbeck, T	2
Puts, NA	2
Watson, J	1
Aguila, MR	2
Leaver, AM	2
Kanao-Kanda, M	1
Kanda, H	1
Liu, S	1
Roy, S	1
Toborek, M	1
Hao, S	1
Legarreta, MD	1
Sheth, C	1
Prescot, AP	1
Renshaw, PF	1
McGlade, EC	1
Yurgelun-Todd, DA	1
Wan, L	1
Li, Z	1
Liu, T	1
Chen, X	1
Xu, Q	1
Yao, W	1
Zhang, Y	2
Foster, S	1
Oeltzschner, G	1
Galloway, G	1
Sterling, M	1
Ng, K	1
Refshauge, K	1
Kang, D	1
Hesam-Shariati, N	1
McAuley, JH	1
Alam, M	1
Trost, Z	1
Rae, CD	1
Gustin, SM	1
Glinn, MA	1
Lickteig, AJ	1
Weber, L	1
Recer, S	1
Salske, M	1
Harvey, A	1
Rappold, B	1
Stensland, J	1
Bell, P	1
Correia, CR	1
Soares, AT	1
Azurara, L	1
Palaré, MJ	1
Wiffen, PJ	5
Derry, S	2
Bell, RF	1
Rice, AS	2
Tölle, TR	1
Phillips, T	1
Moore, RA	3
Madden, K	1
Bruera, E	1
Handberg, G	1
Jodoin, M	1
Rouleau, D	1
Larson-Dupuis, C	1
Gosselin, N	1
De Beaumont, L	1
Kopach, O	1
Medvediev, V	1
Krotov, V	1
Borisyuk, A	1
Tsymbaliuk, V	1
Voitenko, N	1
Rai, AS	1
Khan, JS	1
Dhaliwal, J	1
Busse, JW	1
Choi, S	1
Devereaux, PJ	2
Clarke, H	3
Goodman, CW	1
Brett, AS	1
Cooper, TE	2
Heathcote, LC	2
Clinch, J	2
Gold, JI	1
Howard, R	2
Lord, SM	2
Schechter, N	2
Wood, C	2
Krane, E	1
Sethna, N	1
Horne, AW	3
Vincent, K	3
Cregg, R	2
Daniels, J	2
Harper, DE	1
Ichesco, E	1
Schrepf, A	1
Halvorson, M	1
Puiu, T	1
Clauw, DJ	3
Harris, RE	3
Harte, SE	1
Baranowski, A	1
Bhattacharya, S	2
Birch, J	1
Cheong, Y	1
Hewitt, CA	1
Macfarlane, GJ	1
Middleton, L	1
Szubert, W	1
Tracey, I	2
Williams, ACC	1
Fonta, C	1
Salles, JP	1
Ko, MY	1
Jang, EY	1
Lee, JY	1
Kim, SP	1
Whang, SH	1
Lee, BH	2
Kim, HY	2
Yang, CH	2
Cho, HJ	1
Gwak, YS	2
Inquimbert, P	1
Moll, M	1
Latremoliere, A	1
Tong, CK	1
Whang, J	2
Sheehan, GF	1
Smith, BM	1
Korb, E	1
Athié, MCP	1
Babaniyi, O	1
Ghasemlou, N	1
Yanagawa, Y	1
Allis, CD	1
Hof, PR	1
Scholz, J	2
Edwards, RA	1
Bonfanti, G	1
Grugni, R	1
Manca, L	1
Parsons, B	1
Alexander, J	1
Anantharamu, T	1
Govind, MA	1
Li, J	1
Lin, H	1
Huang, Q	1
Wang, T	1
Zhang, S	2
Zhang, Q	1
Rong, Z	1
Xiong, J	1
Wijeysundera, DN	2
Bonin, RP	2
Orser, B	1
Englesakis, M	2
Katz, J	2
Landau, R	1
Bollag, L	1
Ortner, C	1
Moens, M	1
Mariën, P	1
Brouns, R	1
Poelaert, J	1
De Smedt, A	1
Buyl, R	1
Droogmans, S	1
Van Schuerbeek, P	1
Sunaert, S	1
Nuttin, B	1
Rauck, R	1
Coffey, RJ	1
Schultz, DM	1
Wallace, MS	2
Webster, LR	1
McCarville, SE	1
Grigsby, EJ	1
Page, LM	1
Chaparro, LE	1
Smith, SA	1
Gilron, I	2
Carroll, I	1
Curtin, CM	1
Ide, Y	1
Winkelman, JW	1
Gagnon, A	1
Clair, AG	1
Schmidt, PC	2
Ruchelli, G	2
Mackey, SC	2
Carroll, IR	2
Yang, F	1
Derry, WT	1
Vardeh, D	1
Rashiq, S	1
Dick, BD	1
Dickenson, AH	1
Kehlet, H	1
Napadow, V	1
Huggins, JP	1
Pauer, L	1
Kim, J	1
Hampson, J	1
Sundgren, PC	1
Foerster, B	1
Petrou, M	1
Schmidt-Wilcke, T	1
Ravindran, D	1
Dauri, M	1
Lazzari, M	1
Casali, M	1
Tufaro, G	1
Sabato, E	1
Sabato, AF	1
Cheong, YC	1
Smotra, G	1
Williams, AC	1
Zhang, Z	1
Tao, W	1
Hou, YY	1
Wang, W	1
Lu, YG	1
Pan, ZZ	1
Hounnou, P	1
Nicoucar, K	1
Toelle, T	1
Suto, T	1
Eisenach, JC	1
Hayashida, K	1
Sawan, H	1
Chen, AF	1
Viscusi, ER	1
Parvizi, J	1
Hozack, WJ	1
Wagner, K	1
Yang, J	2
Inceoglu, B	1
Hammock, BD	1
Berrocoso, E	1
van Schalkwyk, JM	1
Kachhwah, V	1
Ahmad, Z	1
Mishriky, BM	1
Waldron, NH	1
Habib, AS	1
Hummig, W	1
Kopruszinski, CM	1
Chichorro, JG	1
Hiom, S	1
Patel, GK	1
Newcombe, RG	1
Khot, S	1
Martin, C	1
Zhang, M	1
Xie, F	1
Bao, M	1
Yang, N	1
Shi, R	1
Wang, Z	1
Wu, A	1
Guan, Y	2
Yue, Y	1
Benson, C	1
Mifflin, K	1
Kerr, B	1
Jesudasan, SJ	1
Dursun, S	1
Baker, G	1
Moisset, X	1
de Andrade, DC	1
Bouhassira, D	1
Reddi, D	1
Chu, J	1
Bruyninckx, F	1
Neuhauser, DV	1
Tonsfeldt, KJ	1
Suchland, KL	1
Beeson, KA	1
Lowe, JD	1
Li, MH	1
Ingram, SL	1
You, Z	1
Wang, S	1
Yang, L	2
Sun, Y	1
Mi, W	1
McCabe, MF	1
Shen, S	1
Chen, L	1
Mao, J	1
Belozertseva, I	1
Nagel, J	1
Valastro, B	1
Franke, L	1
Danysz, W	1
Atkinson, JH	1
Slater, MA	1
Capparelli, EV	1
Patel, SM	1
Wolfson, T	1
Gamst, A	1
Abramson, IS	1
Funk, SD	1
Rutledge, TR	1
Wetherell, JL	1
Matthews, SC	1
Zisook, S	1
Garfin, SR	1
Lewis, SC	1
Wu, O	1
Jack, SA	1
Critchley, HO	1
Porter, MA	1
Cranley, D	1
Wilson, JA	1
Lawrence, R	1
Boesen, ML	1
Bygum, A	1
Hertz, JM	1
Zachariassen, G	1
Badiola, IJ	1
Hamada, Y	1
Yamashita, A	1
Tamura, H	1
Narita, M	2
Kuzumaki, N	1
Ortiz-Catalan, M	1
Guðmundsdóttir, RA	1
Kristoffersen, MB	1
Zepeda-Echavarria, A	1
Caine-Winterberger, K	1
Kulbacka-Ortiz, K	1
Widehammar, C	1
Eriksson, K	1
Stockselius, A	1
Ragnö, C	1
Pihlar, Z	1
Burger, H	1
Hermansson, L	1
Almoznino, G	1
Haviv, Y	1
Sharav, Y	1
Benoliel, R	1
Carter, BS	1
Brunkhorst, J	1
Chen, RX	1
Wang, J	1
Liu, FY	1
Cai, J	1
Liao, FF	1
Xu, FQ	1
Yi, M	1
Wan, Y	1
Shanthanna, H	1
Thabane, L	1
Bhandari, M	1
AlAmri, R	1
Rajarathinam, M	1
Kamath, S	1
Ucak, A	1
Onan, B	1
Sen, H	1
Selcuk, I	1
Turan, A	1
Yilmaz, AT	1
Graversen, C	1
Olesen, SS	1
Olesen, AE	1
Steimle, K	1
Farina, D	1
Wilder-Smith, OH	1
Bouwense, SA	1
van Goor, H	1
Drewes, AM	1
Silverman, A	1
Samuels, Q	1
Gikas, H	1
Nawras, A	1
Wei, X	1
Wei, W	1
Reichl, S	1
Augustin, M	1
Zahn, PK	1
Pogatzki-Zahn, EM	1
Mease, PJ	1
Dundon, K	1
Sarzi-Puttini, P	2
Spaeth, M	1
Rizzi, M	1
Janssen, SP	1
Gerard, S	1
Raijmakers, ME	1
Truin, M	1
Van Kleef, M	1
Joosten, EA	1
Streeter, CC	1
Gerbarg, PL	1
Saper, RB	1
Ciraulo, DA	1
Brown, RP	1
Kinney, MA	1
Hooten, WM	1
Cassivi, SD	1
Allen, MS	1
Passe, MA	1
Hanson, AC	1
Schroeder, DR	1
Mantilla, CB	1
Orser, BA	1
Kohno, T	1
Obata, H	1
Buvanendran, A	1
Matsutani, N	1
Kawamura, M	1
Fassoulaki, A	1
Melemeni, A	1
Tsaroucha, A	1
Paraskeva, A	1
Eto, K	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
GABA-WHY Study: Deprescription of Gabapentinoids in Medical Inpatients[NCT04855578]		160 participants (Actual)	Interventional	2021-05-28	Completed
"Preoperative Gabapentin and Its Effects on Postoperative Analgesia in Patients Undergoing Cosmetic Breast Surgery"[NCT05997355]		100 participants (Anticipated)	Interventional	2023-09-01	Not yet recruiting
Gabapentin Regimens and Their Effects on Opioid Consumption[NCT03334903]	Phase 4	77 participants (Actual)	Interventional	2018-05-15	Completed
STTEPP: Safety, Tolerability and Dose Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis[NCT05603702]	Phase 1	24 participants (Anticipated)	Interventional	2023-03-17	Recruiting
A 13 Week, Double-Blind, Placebo-Controlled Phase 4 Trial of Pregabalin (CI-1008, 600 mg/Day) for Relief of Pain in Subjects With Painful Diabetic Peripheral Neuropathy[NCT00159679]	Phase 4	167 participants (Actual)	Interventional	2004-09-30	Completed
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial of Pregabalin Versus Placebo in the Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy[NCT00143156]	Phase 3	450 participants	Interventional	2005-03-31	Completed
A 14-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Evaluate The Safety And Efficacy Of Pregabalin (150mg-600mg/Day) Using A Flexible Optimal Dose Schedule In Patients With Painful Diabetic Peripheral Neuropathy (DPN).[NCT00156078]	Phase 4	450 participants	Interventional	2005-01-31	Completed
Randomized, Double-Blind, Multicenter, Placebo-Controlled Study To Evaluate Efficacy And Safety Of Pregabalin (CI-1008) In The Treatment For Pain Associated With Diabetic Peripheral Neuropathy[NCT00553475]	Phase 3	314 participants (Actual)	Interventional	2007-10-31	Completed
EEG Mapping During High Frequency/High Density Spinal Cord Stimulation in Patients With Failed Back Surgery Syndrome[NCT02751216]		20 participants (Actual)	Interventional	2016-05-31	Completed
STructural And FunCTional Brain Alterations by HIgh FrequenCy Spinal Cord Stimulation: a Combined Voxel-based Morphometry and Resting State Functional Connectivity Study[NCT02650362]		10 participants (Actual)	Interventional	2016-01-31	Completed
StruCtuRal And FuncTional Brain Alterations by Conventional Spinal Cord Stimulation And High DensitY Stimulation: a Combined Voxel-based Morphometry and Resting State Functional Connectivity Study[NCT02650349]		11 participants (Actual)	Interventional	2016-01-31	Completed
A Randomized Double Blind, Placebo-controlled, Dose Response Study of Intraspinal Gabapentin (MDT2004) in Subjects With Chronic, Intractable Pain.[NCT00414466]	Phase 2	254 participants (Actual)	Interventional	2006-12-31	Terminated (stopped due to Study closed and subject follow-up completed following analysis of blinded study data.)
Effect of Preoperative Gabapentin on Postoperative Pain Associated With Ureteroscopy and Stents Insertion: a Double Blind, Randomized, Placebo Controlled Trial[NCT03151746]	Phase 4	20 participants (Actual)	Interventional	2018-01-14	Terminated (stopped due to Insufficient enrollment)
Effects of Pre-operative Oral Pregabalin on Post Operative Morphine Consumption After Abdominal Hysterectomy With/Without Salpingo-oophorectomy Under Spinal Anesthesia With Intrathecal Morphine[NCT02285010]	Phase 4	125 participants (Actual)	Interventional	2014-11-30	Completed
Single Dose Preoperative Gabapentin Use in Minimally Invasive Hysterectomy for Acute Pain Management[NCT02703259]	Phase 4	137 participants (Actual)	Interventional	2016-06-30	Completed
Efficacy of Different Doses of Pregabalin as a Multimodal Analgesic Agent in Postoperative Pain Control After Total Knee Arthroplasty - A Randomized Controlled Trial[NCT05447364]	Phase 4	82 participants (Anticipated)	Interventional	2021-07-01	Recruiting
Labor Pain and Postpartum Behavioral Health Outcomes Study[NCT02692404]		199 participants (Actual)	Observational	2016-01-31	Completed
Opioid-Free Shoulder Arthroplasty[NCT03540030]	Phase 4	86 participants (Actual)	Interventional	2016-09-30	Completed
Effect of Two Different Doses of Oral Pregabalin Premedication for Postoperative Pain Relief After Gynecological Surgeries[NCT04708353]		90 participants (Anticipated)	Interventional	2020-08-20	Recruiting
Psychosocial and Psychophysical Factors Influencing the Effect of Preemptive Systemic Analgesia in Combination With Regional Anesthesia on Postoperative Pain Following Upper Limb Surgery[NCT05248152]		90 participants (Anticipated)	Interventional	2022-01-13	Recruiting
Efficacy of Antidepressants in Chronic Back Pain[NCT00108550]	Phase 2	108 participants (Actual)	Interventional	2004-10-31	Completed
Phantom Motor Execution Via Myoelectric Pattern Recognition, Virtual and Augmented Reality, and Serious Gaming as a Treatment of Phantom Limb Pain[NCT03112928]		77 participants (Actual)	Interventional	2017-05-08	Completed
Myoelectrically Controlled Augmented Reality and Gaming for the Treatment of Phantom Limb Pain[NCT02281539]		14 participants (Actual)	Interventional	2014-09-30	Completed
The Effects of Targeted Phantom Motor Execution, Prosthetic Embodiment, and Surgical Closure on Phantom Limb Control, and Physical Function in People With Unilateral (Single) Transtibial (Below-the-knee) Amputation[NCT05247827]		30 participants (Actual)	Interventional	2022-06-01	Completed
Mindful SensoriMotor Therapy With Brain Modulation for the Treatment of Pain in Individuals With Disarticulation or Nerve Injuries: A Single Arm Clinical Trial[NCT04897425]		8 participants (Anticipated)	Interventional	2022-06-01	Not yet recruiting
Electromyography-controlled Virtual Reality and Serious Gaming to Improve Upper Extremity Function in Chronic Stroke Patients[NCT04154371]		6 participants (Actual)	Interventional	2019-11-11	Active, not recruiting
Pregabalin for the Treatment of Abdominal Pain From Adhesions: Placebo Controlled Trial[NCT00310765]	Phase 4	18 participants (Actual)	Interventional	2006-03-31	Terminated (stopped due to Study was terminated by the sponsor due to low accrual.)
Application of Vagal Stimulation by Cold Face Mask in Exposure and Response Prevention for Obsessive Compulsive Disorder[NCT02196090]		10 participants (Anticipated)	Interventional	2014-07-31	Recruiting
Administration of Pre-Operative Gabapentin to Patients Undergoing Laparoscopy: A Prospective Double-blinded, Placebo Controlled Randomized Study[NCT02359110]	Phase 4	112 participants (Actual)	Interventional	2015-06-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Surgical site pain. Scale 0-10, with 0 best and 10 worst (NCT03334903)
Timeframe: 2-3 months after surgery (at 2nd postoperative appointment)

"VAS Score 2: How Much Pain do You Feel in Your Operative Site When Moving?"

Intervention	score on 10-point scale (Mean)
Standard of Care	2.26
Postoperative Gabapentin Regimen	2.46

Surgical site pain. Scale 0-10, with 0 best and 10 worst. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).

"VAS Score 3: How Well Are You Sleeping?"

Intervention	score on a 10-point scale (Mean)
Standard of Care	3.84
Postoperative Gabapentin Regimen	3.54

Sleep quality. Scale 0-10 with 0 worst and 10 best. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).

"VAS Score 4: How Bad is Your Nausea?"

Intervention	score on a 10-point scale (Mean)
Standard of Care	5.73
Postoperative Gabapentin Regimen	6.38

Nausea. Scale 0-10, with 0 best and 10 worst. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).

"VAS Score 5: How Satisfied Are You With Your Pain Management?"

Intervention	score on a 10-point scale (Mean)
Standard of Care	0.36
Postoperative Gabapentin Regimen	0.17

Satisfaction. Scale 0-10 with 0 worst and 10 best. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).

Days Taking Opioids

Intervention	score on a 10-point scale (Mean)
Standard of Care	7.83
Postoperative Gabapentin Regimen	8.48

Number of days until patients are finished consuming opioid medications after discharge. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).

Opioid Consumption

Intervention	days (Mean)
Standard of Care	14.8
Postoperative Gabapentin Regimen	18.7

Mean opioid consumption, measured in mg of morphine equivalents. (NCT03334903)
Timeframe: 2-3 months following surgery (total amount measured at second postoperative appointment; means assessed afterwards).

Change From Baseline at Week 1 in Mean Weekly Pain Scores

Intervention	morphine equivalents (Mean)
Standard of Care	287.0
Postoperative Gabapentin Regimen	281.1

"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 1.~Change from baseline: Score at Week 1 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 1

Change From Baseline at Week 10 in Mean Weekly Pain Scores

Intervention	score on scale (Least Squares Mean)
Placebo	-0.39
Pregabalin 300 mg/Day	-0.82
Pregabalin 600 mg/Day	-1.14

"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 10.~Change from baseline: Score at Week 10 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 10

Change From Baseline at Week 11 in Mean Weekly Pain Scores

Intervention	score on scale (Least Squares Mean)
Placebo	-1.23
Pregabalin 300 mg/Day	-1.93
Pregabalin 600 mg/Day	-2.10

"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 11.~Change from baseline: Score at Week 11 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 11

Change From Baseline at Week 12 in Mean Weekly Pain Scores

Intervention	score on scale (Least Squares Mean)
Placebo	-1.32
Pregabalin 300 mg/Day	-1.95
Pregabalin 600 mg/Day	-2.09

"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 12.~Change from baseline: Score at Week 12 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 12

Change From Baseline at Week 13 in Mean Weekly Pain Scores

Intervention	score on scale (Least Squares Mean)
Placebo	-1.36
Pregabalin 300 mg/Day	-2.01
Pregabalin 600 mg/Day	-2.13

"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 13.~Change from baseline: Score at Week 13 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 13

Change From Baseline at Week 2 in Mean Weekly Pain Scores

Intervention	score on scale (Least Squares Mean)
Placebo	-1.38
Pregabalin 300 mg/Day	-2.04
Pregabalin 600 mg/Day	-2.12

"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 2.~Change from baseline: Score at Week 2 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 2

Change From Baseline at Week 3 in Mean Weekly Pain Scores

Intervention	score on scale (Least Squares Mean)
Placebo	-0.57
Pregabalin 300 mg/Day	-1.17
Pregabalin 600 mg/Day	-1.80

"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 3.~Change from baseline: Score at Week 3 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 3

Change From Baseline at Week 4 in Mean Weekly Pain Scores

Intervention	score on scale (Least Squares Mean)
Placebo	-0.80
Pregabalin 300 mg/Day	-1.40
Pregabalin 600 mg/Day	-1.93

"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 4.~Change from baseline: Score at Week 4 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 4

Change From Baseline at Week 5 in Mean Weekly Pain Scores

Intervention	score on scale (Least Squares Mean)
Placebo	-0.89
Pregabalin 300 mg/Day	-1.53
Pregabalin 600 mg/Day	-2.00

"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 5.~Change from baseline: Score at Week 5 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 5

Change From Baseline at Week 6 in Mean Weekly Pain Scores

Intervention	score on scale (Least Squares Mean)
Placebo	-0.91
Pregabalin 300 mg/Day	-1.57
Pregabalin 600 mg/Day	-2.07

"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 6.~Change from baseline: Score at Week 6 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 6

Change From Baseline at Week 7 in Mean Weekly Pain Scores

Intervention	score on scale (Least Squares Mean)
Placebo	-0.94
Pregabalin 300 mg/Day	-1.72
Pregabalin 600 mg/Day	-2.06

"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 7.~Change from baseline: Score at Week 7 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 7

Change From Baseline at Week 8 in Mean Weekly Pain Scores

Intervention	score on scale (Least Squares Mean)
Placebo	-1.04
Pregabalin 300 mg/Day	-1.76
Pregabalin 600 mg/Day	-2.13

"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 8.~Change from baseline: Score at Week 8 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 8

Change From Baseline at Week 9 in Mean Weekly Pain Scores

Intervention	score on scale (Least Squares Mean)
Placebo	-1.18
Pregabalin 300 mg/Day	-1.85
Pregabalin 600 mg/Day	-2.12

"The mean change from baseline in mean weekly pain score from daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) at Week 9.~Change from baseline: Score at Week 9 minus score at baseline" (NCT00553475)
Timeframe: From baseline to Week 9

Change From Baseline in Mean Sleep Interference Scores

Intervention	score on scale (Least Squares Mean)
Placebo	-1.20
Pregabalin 300 mg/Day	-1.93
Pregabalin 600 mg/Day	-2.06

The mean change from baseline in the weekly mean sleep interference score at study endpoint. Score range is from 0-10. Higher scores indicate more severe interference with sleep. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Overall Sleep Problems Index

Intervention	score on scale (Least Squares Mean)
Placebo	-0.74
Pregabalin 300 mg/Day	-1.59
Pregabalin 600 mg/Day	-1.36

The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for overall sleep problems index ranges from 0-100. Higher scores indicate more of the attribute. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Quantity of Sleep

Intervention	score on scale (Least Squares Mean)
Placebo	-7.91
Pregabalin 300 mg/Day	-11.45
Pregabalin 600 mg/Day	-9.73

The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for quantity of sleep ranges from 0-24. Higher scores indicate more of the attribute named in the subscale. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Sleep Adequacy

Intervention	score on scale (Least Squares Mean)
Placebo	0.37
Pregabalin 300 mg/Day	0.69
Pregabalin 600 mg/Day	0.54

The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for sleep adequacy ranges from 0-100. Higher scores indicate more of the attribute. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Sleep Disturbance

Intervention	score on scale (Least Squares Mean)
Placebo	12.08
Pregabalin 300 mg/Day	17.69
Pregabalin 600 mg/Day	21.73

The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for sleep disturbance ranges from 0-100. Higher scores indicate more severe pain. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Sleep Shortness of Breath or Headache

Intervention	score on scale (Least Squares Mean)
Placebo	-9.03
Pregabalin 300 mg/Day	-15.40
Pregabalin 600 mg/Day	-12.81

The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for sleep shortness of breath or headache ranges from 0-100. Higher scores indicate more of the attribute. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Snoring

Intervention	score on scale (Least Squares Mean)
Placebo	-1.63
Pregabalin 300 mg/Day	-3.02
Pregabalin 600 mg/Day	-4.47

The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for snoring ranges from 0-100. Higher scores indicate more of the attribute. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

Change From Baseline in Medical Outcomes Study (MOS) - Sleep Scale: Somnolence

Intervention	score on scale (Least Squares Mean)
Placebo	-6.00
Pregabalin 300 mg/Day	-5.96
Pregabalin 600 mg/Day	-1.56

The mean change from baseline in Medical Outcomes Study - Sleep Scale Scores at study endpoint. Score for somnolence ranges from 0-100. Higher scores indicate more of the attribute. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Bodily Pain

Intervention	score on scale (Least Squares Mean)
Placebo	-2.96
Pregabalin 300 mg/Day	0.83
Pregabalin 600 mg/Day	4.83

The mean change from baseline in Short-Form 36-Item Health Survey Scores at study endpoint. Short-Form 36-Item Health Survey is scored from 0-100 with higher scores reflecting better patient status. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

Change From Baseline in Short Form 36-Item (SF-36) Health Survey: General Health Perception

Intervention	score on scale (Least Squares Mean)
Placebo	10.34
Pregabalin 300 mg/Day	11.84
Pregabalin 600 mg/Day	12.89

Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Mental Health

Intervention	score on scale (Least Squares Mean)
Placebo	2.31
Pregabalin 300 mg/Day	3.29
Pregabalin 600 mg/Day	4.40

Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Physical Functioning

Intervention	score on scale (Least Squares Mean)
Placebo	3.84
Pregabalin 300 mg/Day	5.33
Pregabalin 600 mg/Day	7.81

Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Role Limitations-Emotional

Intervention	score on scale (Least Squares Mean)
Placebo	2.70
Pregabalin 300 mg/Day	2.43
Pregabalin 600 mg/Day	3.86

Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Role Limitations-Physical

Intervention	score on scale (Least Squares Mean)
Placebo	4.13
Pregabalin 300 mg/Day	5.05
Pregabalin 600 mg/Day	6.35

Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Social Functioning

Intervention	score on scale (Least Squares Mean)
Placebo	4.38
Pregabalin 300 mg/Day	2.28
Pregabalin 600 mg/Day	3.97

Change From Baseline in Short Form 36-Item (SF-36) Health Survey: Vitality

Intervention	score on scale (Least Squares Mean)
Placebo	3.00
Pregabalin 300 mg/Day	8.06
Pregabalin 600 mg/Day	11.16

Change From Baseline in Short-Form McGill Pain Questionnaire: Affective Scores

Intervention	score on scale (Least Squares Mean)
Placebo	5.28
Pregabalin 300 mg/Day	4.20
Pregabalin 600 mg/Day	12.87

The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Affective score ranges from 0-12. Higher scores indicate more severe pain. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

Change From Baseline in Short-Form McGill Pain Questionnaire: Present Pain Intensity Scores

Intervention	score on scale (Least Squares Mean)
Placebo	-0.83
Pregabalin 300 mg/Day	-1.43
Pregabalin 600 mg/Day	-1.39

The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Present pain intensity score ranges from 0-5. Higher scores indicate more severe pain. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

Change From Baseline in Short-Form McGill Pain Questionnaire: Sensory Scores

Intervention	score on scale (Least Squares Mean)
Placebo	-0.59
Pregabalin 300 mg/Day	-0.80
Pregabalin 600 mg/Day	-0.96

The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Sensory score ranges from 0-33. Higher scores indicate more severe pain. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

Change From Baseline in Short-Form McGill Pain Questionnaire: Total Scores

Intervention	score on scale (Least Squares Mean)
Placebo	-2.82
Pregabalin 300 mg/Day	-4.60
Pregabalin 600 mg/Day	-4.95

The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Total score ranges from 0-45. Higher scores indicate more severe pain. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

Change From Baseline in Short-Form McGill Pain Questionnaire: Visual Analogue Scale Scores

Intervention	score on scale (Least Squares Mean)
Placebo	-3.68
Pregabalin 300 mg/Day	-6.03
Pregabalin 600 mg/Day	-6.36

The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Visual Analogue Scale Score ranges from 0-100 mm. Higher scores indicate more severe pain. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

Change From Baseline to Study Endpoint in Mean Weekly Pain Scores

Intervention	mm (Least Squares Mean)
Placebo	-16.92
Pregabalin 300 mg/Day	-24.19
Pregabalin 600 mg/Day	-24.41

Change from baseline: Score at study endpoint minus score at baseline. Study endpoint is defined as the mean of the last seven entries of the daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) while on study medication up to and including day after last dose. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

Change From Baseline to Study Endpoint in Mean Weekly Pain Scores by Groups of Subjects With Expected Similar Plasma Concentrations

Intervention	score on scale (Least Squares Mean)
Placebo	-1.20
Pregabalin 300 mg/Day	-1.82
Pregabalin 600 mg/Day	-1.94

Change from baseline: Score at study endpoint minus score at baseline. Study endpoint is defined as the mean of the last seven entries of the daily pain diary using the 11-point numerical rating scale 0(no pain) to 10(worst possible pain) while on study medication up to and including day after last dose. Subjects are classified by exposure to pregabalin, which is estimated by creatinine clearance (CLcr). (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

Clinical Global Impression of Change

Intervention	score on scale (Least Squares Mean)
Placebo	-1.27
Expected Exposure Pregabalin 300 mg/Day	-1.93
Expected Exposure Pregabalin 600 mg/Day	-1.90

Clinical Global Impression of Change is a clinician-rated instrument that measures change in patient's overall status on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). (NCT00553475)
Timeframe: Week 13 or up to discontinuation

Number of Responders

Intervention	score on scale (Mean)
Placebo	3.3
Pregabalin 300 mg/Day	2.9
Pregabalin 600 mg/Day	2.7

A responder is defined as a subject with a 50% reduction in weekly mean pain score from baseline to study endpoint. (NCT00553475)
Timeframe: From baseline to Week 13 or up to study discontinuation (Study Endpoint)

Patient Global Impression of Change

Intervention	participants (Number)
Placebo	29
Pregabalin 300 mg/Day	39
Pregabalin 600 mg/Day	16

The Patient Global Impression of Change is a patient-rated instrument that measures change in patient's overall status on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). (NCT00553475)
Timeframe: Week 13 or up to discontinuation

Changes in a Pain Rating Scale After 3 Weeks of Blinded Treatment.

Intervention	score on scale (Mean)
Placebo	3.4
Pregabalin 300 mg/Day	3.2
Pregabalin 600 mg/Day	2.8

Average pain score calculated over last 7 days of baseline minus average pain score calculated over last 7 days of follow-up using the Numeric Pain Rating Scale where 0=no pain, 10=worst possible pain. (NCT00414466)
Timeframe: Baseline and Post-randomization Day 22

Number of Participants With Treatment-emergent Adverse Events

Evaluation of adverse event profiles between placebo and active treatment groups. (NCT00414466)
Timeframe: Randomization to Post-randomization Day 29 (includes dose reduction)

Responder Analysis Between Active Treatment and Placebo Groups.

Responders were subjects that reported at least a 30% decrease in average daily pain scores between baseline and Day 22. (NCT00414466)
Timeframe: Baseline to Post-randomization Day 22

24 Hour Pain Burden

Pain scores using an 11 point numeric pain rating scale 0=no pain 10 = worst pain imaginable (NCT03151746)
Timeframe: 24 hours after surgery

48 Hours Morphine Equivalents Consumed.

Total morphine equivalents in milligrams consumed during the first 48 hours after surgery. (NCT03151746)
Timeframe: Up to 48 hours after surgery

QOR 40 Questionnaire Scores

Evaluate quality of recovery using the Quality of Recovery 40 (QoR 40) questionnaire a 40 question survey scored from 40 ( poor recovery) to 200 high (good recovery) 48 hours after the surgical procedure. (NCT03151746)
Timeframe: 48 hours after surgical procedure

Time to First Analgesia

Time to first analgesia is recorded from IV PCA. (NCT02285010)
Timeframe: 24 hours

Pain Scores on the Visual Analog Scale

"Pain score is evaluated by nurses using Numerical Rating Scale (NRS)~Minimum score 0 (no pain), Maximum score 10 (worst imaginable pain), lower scores mean a better outcome" (NCT02285010)
Timeframe: 24 hours

Post Operative Morphine Consumption

Cumulative morphine consumption in the first 24 hours is recorded from IV PCA (NCT02285010)
Timeframe: 6, 12, and 24 hours after operation

Numbers of Participants With Adverse Events as a Measure of Safety and Tolerability

Measure sedation score by evaluate and observe; measure pruritus, PONV, dizziness, visual disturbance using questionnaire (NCT02285010)
Timeframe: 24 hours

Narcotic Use at 2 Weeks Postop

Assessment of the amount of narcotic use postoperatively at 2 weeks. will use opioid equivalence table to convert all narcotic use to oxycodone equivalents (NCT02703259)
Timeframe: 2 weeks

Narcotic Use at 24 Hours Postop

Assessment of the amount of narcotic use postoperatively at 24 hours. will use opioid equivalence table to convert all narcotic use to oxycodone equivalents (NCT02703259)
Timeframe: 24 hours

Subjective Pain at 2 Weeks Postop

"Assessment of the subject pain score postoperatively at 2 weeks. will use a numeric analog scale from 0-10.~The pain scale ranging from 0-10 with 0 representing No Pain and 10 representing the Worst Pain Possible" (NCT02703259)
Timeframe: 2 weeks

Subjective Pain at 24 Hours Postoperative

Pain score assesses patient subjective pain via patient reported numeric analogue scale, range 0-10 with 0 being no pain and 10 being severe pain. (NCT02703259)
Timeframe: 24 hours

Number of Patient With Gabapentin Adverse Effects at 2 Weeks Postoperatively

Will assess for known symptoms of gabapentin postoperatively at 2 weeks. We will survey subjects regarding their experience of the following symptoms: dizziness/drowsiness, fatigue, loss of balance, blurry vision, tremulousness, swelling, nausea, vomiting, diarrhea, and allergic reaction (NCT02703259)
Timeframe: 2 weeks

Number of Patient With Gabapentin Adverse Effects at 24 Hours Postoperatively

Will assess for known symptoms of gabapentin postoperatively at 24 hours. We will survey subjects regarding their experience of the following symptoms: dizziness/drowsiness, fatigue, loss of balance, blurry vision, tremulousness, swelling, nausea, vomiting, diarrhea, and allergic reaction (NCT02703259)
Timeframe: 24 hours

ASES

American Shoulder and Elbow Surgeons (ASES) Shoulder Score for pain and function. Range 0-100. Low score = worse shoulder condition. Function, disability, and pain subscores (all ranges 0-50), and are summed for total ASES score. (NCT03540030)
Timeframe: 2 Weeks

Morphine Use

Morphine milli-equivalents In-hospital post-operative. Continuous scale of MME, no defined better/worse. Measured as number and dose of medications taken. For example, if the patient received an opioid, the drug and dose was recorded and converted to MME. A time frame of when to assess opioid use in-hospital post-operative was not used but was a continuous monitor for rescue opioid from in-hospital post-operative through discharge. (NCT03540030)
Timeframe: In-hospital Stay

Post Op Pain

Pain at patient discharge or 24-hours, whichever comes first - measured on a 0 (no pain) -10 (worst possible pain) numeric rating scale (NRS). A score of 0(no pain) is preferable to 10(worst possible pain) (NCT03540030)
Timeframe: 24 hours

Simple Shoulder Test

Simple Shoulder Test (SST) activity score. Range 0-12. 0 = worse activity score. (NCT03540030)
Timeframe: 2 Months

Simple Shoulder Test

Simple Shoulder Test (SST) activity score. Range 0-12. 0 = worse activity score. (NCT03540030)
Timeframe: 2 Weeks

Additional Post Op Pain

post-operative pain: measured on a 0 (no pain) -10 (worst) numeric rating scale (NRS) at 6hrs, 12hrs, 2 weeks, and 2 months. A score of 0(no pain) is preferable to 10(worst possible pain) (NCT03540030)
Timeframe: 6hrs, 12hrs, 2weeks, 2 months

Constipation

Falls

Nausea

Pain Satisfaction

Satisfaction with overall pain using Numeric Pain Rating (NRS) scale. yes, no. No being better than yes. (NCT03540030)
Timeframe: 2 Months

Pain Satisfaction

Satisfaction with overall pain using Numeric Pain Rating (NRS) scale. yes, no. No being better than yes. (NCT03540030)
Timeframe: 2 Weeks

quality of life using VR-12 subscores. Physical Health (PCS) subscore and Mental Health (MCS) subscore, not summed. Range reported in weighted units. Physical Health subscore: 1 point increase in PCS is associated with 6% lower total health care expenditures, 5% lower pharmacy expenditures, 9% lower rate of hospital inpatient visits, 4% lower rate of medical provider visits, 5% lower rate of hospital outpatient visits. Mental Health sub score a 1 point increase in MCS is associated with 7% lower total health care expenditures, 4% lower pharmacy expenditures, 15% lower rate of hospital inpatient visits, and 4% lower rate of medical provider visits. Both PCS/MCS are score 0-100 with 100 indicating the highest level of health. (NCT03540030)
Timeframe: 2 Months

Roland and Morris Disability Index Scores Adjusted for Time

"This questionnaire measures disability in everyday function due to back pain. It is a 24-item checklist asking patients to endorse whether or not back pain limits activities they normally do (eg, I stay at home most of the time because of my back). Scores range from 0 to 24, with higher scores indicating greater disability in everyday function due to back pain. The single values reported below represent adjusted means of scores over all time points." (NCT00108550)
Timeframe: Baseline to Week 12 with Interim Measurement at Weeks 1, 2, 3, 4, 5, 7 and 9

Transformed Descriptor Differential Scale-Pain Intensity Scores Adjusted for Time

"Self-report measure of current pain intensity of chronic back pain. Participants rate pain on a 20 point scale as being greater or less intense relative to 12 adjectival descriptor word anchors (eg, greater or less than faint, moderate, strong). Scores range from 0 to 20 with higher scores indicating higher pain intensity. Prior to analysis an order-preserving mean-matching variance-stabilizing transformation was applied to this measure placing it on a continuous 0-1.5 scale. The single values reported below represent adjusted means of transformed pain intensity over all time points." (NCT00108550)
Timeframe: Baseline to Week 12 with Interim Measurement at Weeks 1, 2, 3, 4, 5, 7 and 9

Absolute Adhesional Abdominal Pain Score Assessed at Baseline Through Week 12 in Patients Treated With Pregabalin 150-300 mg Daily Compared With Patients Given Look Alike Placebo

Patients were randomized to pregabalin or placebo 75 mg twice a day. Patients were allowed to double the dose on day 3 if adequate pain relief was not obtained. Abdominal pain reduction was measured on a Likert scale. A Likert scale assumes the intensity of pain is linear on a continuum from no pain at level 0 to severe pain at level 10. Patients were required to complete a daily dairy recording pain using the Likert 11-point numeric scale. The primary end point was a positive change in the daily pain diary of 2 points from each patient's baseline at weeks 8 after the completion of the blinded study and at week 12 during the open label portion of the study. After 7 weeks all patients are randomized to study drug pregabalin 150 to 300 mg daily for 4 additional weeks after a one week wash out with no medication. (NCT00310765)
Timeframe: Baseline and week 2 through week 12

Improved Sleep Scores

Absolute Improvement in Sleep by assessing Mean Daily sleep interference scores as measured weekly starting at baseline and reported weekly through week 12 excluding the first week. This score is an 11 point scale the documents the pain interference in sleep in the preceding 24 hours. 0 is no interference and 10 is pain completely disrupted sleep in the previous 24 hours. During the study patients recorded a daily sleep interference score based on 11 point scale (0-10) with the higher number being the most sleep interference (NCT00310765)
Timeframe: Baseline and week 2 through week 12

Total Morphine Consumption

NRS (Numerical Rating Scale)

The NRS is a numerical scale ranging from 0-10 implemented with adults. Having no pain is rated as a 0 and the worst pain the patient could tolerate is rated as a 10. (NCT02359110)
Timeframe: 2-8 hours

VAS (Visual Analog Scale)

"The VAS is scored using a horizontal line 100mm in length. The scale is anchored by no pain (score of 0) and worst pain (score of 100)." (NCT02359110)
Timeframe: 2 -6 hours

Intervention	Scores on a scale (Mean)
1 Placebo	0.48
2 Gabapentin Low	0.40
3 Gabapentin Medium	0.10
4 Gabapentin High	-0.02

Intervention	mg (Median)
	Morphine consumption 6 hr	Morphine consumption 12 hr	Morphine consumption 24 hr
Placebo	1	1	4
Pregabalin	0	1	5

Intervention	Participants (Count of Participants)
	Pruritus72177998				Pruritus72177999	Nausea72177998	Nausea72177999	Vomiting72177998	Vomiting72177999	Dizziness72177998	Dizziness72177999	Visual disturbance72177998	Visual disturbance72177999
	No	Mild	Moderate	Severe
Pregabalin	17
Placebo	35
Pregabalin	31
Placebo	15
Pregabalin	10
Placebo	1
Pregabalin	3
Placebo	18
Pregabalin	23
Placebo	24
Pregabalin	21
Placebo	16
Placebo	31
Pregabalin	38
Placebo	10
Pregabalin	9
Placebo	12
Pregabalin	8
Placebo	5
Pregabalin	6
Pregabalin	14
Pregabalin	39
Placebo	9
Pregabalin	7
Pregabalin	1
Placebo	51
Pregabalin	45
Placebo	7
Pregabalin	16
Placebo	0
Pregabalin	0

Intervention	Participants (Count of Participants)
	Dizziness	Blurred vision	Somnolence	Difficulty walking	Tremulousness	Nausea	Vomiting
Control	8	3	21	5	2	7	1
Gabapentin	12	4	18	5	4	12	0

Intervention	score on a scale (Median)
	6 Hrs	12 hrs	2 weeks	2 months
Non-Opioid Intervention	0.0	0	0.82	0
Observational	2	4	1.3	0.7

Intervention	units on a scale (Mean)
	baseline pain score	week 2	week 3	week 4	week 5	week 6	week 7	week 8 open label with no study medication	week 9 open label	week 10 open label	week 11 open label	week 12 open label
Patients Treated With Placebo	5.8	5.22	4.64	4.84	4.32	3.88	3.92	4.13	2.21	2.27	2.23	1.13
Patients Treated With Pregabalin	6.15	2.87	1.88	3.31	2.72	2.49	2.53	2.46	2.06	1.84	1.46	1.68

Intervention	units on a scale (Mean)
	baseline	week 2	week 3	week 4	week 5	week 6	week 7	week 8 open label no study medication	week 9 open label	week 10 open label	week 11 open label	week 12 open label
Placebo	4.66	3.4	3.26	3.54	3.06	2.74	3.18	3.30	1.70	1.25	1.18	0.56
Pregabalin	3.94	2.20	1.60	1.68	1.68	1.55	1.6	1.82	1.31	1.37	1.39	1.01

Intervention	units on a scale (Least Squares Mean)
	Hour 2	Hour 4	Hour 6	Hour 8
Gabapentin	3.5	5.4	5.3	5.7
Placebo	3.4	5.5	5.8	5.1

Article	Year
Is gabapentin effective and safe in the treatment of chronic pelvic pain in women: a systematic review and meta-analysis. International urogynecology journal, 2022, Volume: 33, Issue:5 Topics: Amines; Analgesics; Chronic Pain; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyri	2022
Brain GABA and glutamate levels across pain conditions: A systematic literature review and meta-analysis of 1H-MRS studies using the MRS-Q quality assessment tool. NeuroImage, 2020, 04-15, Volume: 210 Topics: Chronic Pain; gamma-Aminobutyric Acid; Glutamic Acid; Glutamine; Humans; Migraine Disorders; Musculo	2020
Viral Vector-Mediated Gene Transfer of Glutamic Acid Decarboxylase for Chronic Pain Treatment: A Literature Review. Human gene therapy, 2020, Volume: 31, Issue:7-8 Topics: Accessory Nerve Injuries; AIDS-Associated Nephropathy; Animals; Chronic Pain; Diabetic Neuropathies;	2020
Epoxyeicosatrienoic acids: Emerging therapeutic agents for central post-stroke pain. Pharmacological research, 2020, Volume: 159 Topics: Analgesics; Animals; Brain; Chronic Pain; Eicosanoids; gamma-Aminobutyric Acid; Humans; Inflammation	2020
Gabapentin for chronic neuropathic pain in adults. The Cochrane database of systematic reviews, 2017, 06-09, Volume: 6 Topics: Adult; Amines; Analgesics; Chronic Disease; Chronic Pain; Cyclohexanecarboxylic Acids; Diabetic Neur	2017
[Pharmacological treatment of chronic non-cancer pain]. Ugeskrift for laeger, 2017, Jun-26, Volume: 179, Issue:26 Topics: Analgesics, Opioid; Antidepressive Agents, Tricyclic; Chronic Pain; Drug Substitution; Fibromyalgia;	2017
The clinical utility of repetitive transcranial magnetic stimulation in reducing the risks of transitioning from acute to chronic pain in traumatically injured patients. Progress in neuro-psychopharmacology & biological psychiatry, 2018, 12-20, Volume: 87, Issue:Pt B Topics: Acute Pain; Animals; Chronic Pain; Disease Progression; gamma-Aminobutyric Acid; Humans; Transcrania	2018
Preoperative pregabalin or gabapentin for acute and chronic postoperative pain among patients undergoing breast cancer surgery: A systematic review and meta-analysis of randomized controlled trials. Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 2017, Volume: 70, Issue:10 Topics: Amines; Analgesics; Breast Neoplasms; Chronic Pain; Cyclohexanecarboxylic Acids; Female; Gabapentin;	2017
Preoperative pregabalin or gabapentin for acute and chronic postoperative pain among patients undergoing breast cancer surgery: A systematic review and meta-analysis of randomized controlled trials. Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 2017, Volume: 70, Issue:10 Topics: Amines; Analgesics; Breast Neoplasms; Chronic Pain; Cyclohexanecarboxylic Acids; Female; Gabapentin;	2017
Preoperative pregabalin or gabapentin for acute and chronic postoperative pain among patients undergoing breast cancer surgery: A systematic review and meta-analysis of randomized controlled trials. Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 2017, Volume: 70, Issue:10 Topics: Amines; Analgesics; Breast Neoplasms; Chronic Pain; Cyclohexanecarboxylic Acids; Female; Gabapentin;	2017
Preoperative pregabalin or gabapentin for acute and chronic postoperative pain among patients undergoing breast cancer surgery: A systematic review and meta-analysis of randomized controlled trials. Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 2017, Volume: 70, Issue:10 Topics: Amines; Analgesics; Breast Neoplasms; Chronic Pain; Cyclohexanecarboxylic Acids; Female; Gabapentin;	2017
Antidepressants for chronic non-cancer pain in children and adolescents. The Cochrane database of systematic reviews, 2017, 08-05, Volume: 8 Topics: Abdominal Pain; Adolescent; Amines; Amitriptyline; Analgesics; Antidepressive Agents; Child; Chronic	2017
Antiepileptic drugs for chronic non-cancer pain in children and adolescents. The Cochrane database of systematic reviews, 2017, 08-05, Volume: 8 Topics: Adolescent; Amines; Amitriptyline; Anticonvulsants; Child; Chronic Pain; Complex Regional Pain Syndr	2017
The efficacy of gabapentin in reducing pain intensity and morphine consumption after breast cancer surgery: A meta-analysis. Medicine, 2018, Volume: 97, Issue:38 Topics: Amines; Breast Neoplasms; Chronic Pain; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Amino	2018
Chronic pain after childbirth. International journal of obstetric anesthesia, 2013, Volume: 22, Issue:2 Topics: Acute Pain; Adrenergic alpha-Agonists; Adult; Amines; Analgesics; Anesthetics, Dissociative; Cesarea	2013
Pharmacotherapy for the prevention of chronic pain after surgery in adults. The Cochrane database of systematic reviews, 2013, Jul-24, Issue:7 Topics: Adrenal Cortex Hormones; Adult; Amines; Analgesics; Chronic Pain; Cyclohexanecarboxylic Acids; Femal	2013
Management of chronic pain following nerve injuries/CRPS type II. Hand clinics, 2013, Volume: 29, Issue:3 Topics: Amines; Antidepressive Agents, Tricyclic; Calcium Channel Blockers; Capsaicin; Causalgia; Chronic Pa	2013
Sensory symptoms in restless legs syndrome: the enigma of pain. Sleep medicine, 2013, Volume: 14, Issue:10 Topics: Amines; Analgesics; Chronic Pain; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid;	2013
Perioperative gabapentinoids: choice of agent, dose, timing, and effects on chronic postsurgical pain. Anesthesiology, 2013, Volume: 119, Issue:5 Topics: Amines; Analgesics; Chronic Pain; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid;	2013
Perioperative gabapentinoids: choice of agent, dose, timing, and effects on chronic postsurgical pain. Anesthesiology, 2013, Volume: 119, Issue:5 Topics: Amines; Analgesics; Chronic Pain; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid;	2013
Perioperative gabapentinoids: choice of agent, dose, timing, and effects on chronic postsurgical pain. Anesthesiology, 2013, Volume: 119, Issue:5 Topics: Amines; Analgesics; Chronic Pain; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid;	2013
Perioperative gabapentinoids: choice of agent, dose, timing, and effects on chronic postsurgical pain. Anesthesiology, 2013, Volume: 119, Issue:5 Topics: Amines; Analgesics; Chronic Pain; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid;	2013
Perioperative gabapentinoids: choice of agent, dose, timing, and effects on chronic postsurgical pain. Anesthesiology, 2013, Volume: 119, Issue:5 Topics: Amines; Analgesics; Chronic Pain; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid;	2013
Perioperative gabapentinoids: choice of agent, dose, timing, and effects on chronic postsurgical pain. Anesthesiology, 2013, Volume: 119, Issue:5 Topics: Amines; Analgesics; Chronic Pain; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid;	2013
Perioperative gabapentinoids: choice of agent, dose, timing, and effects on chronic postsurgical pain. Anesthesiology, 2013, Volume: 119, Issue:5 Topics: Amines; Analgesics; Chronic Pain; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid;	2013
Perioperative gabapentinoids: choice of agent, dose, timing, and effects on chronic postsurgical pain. Anesthesiology, 2013, Volume: 119, Issue:5 Topics: Amines; Analgesics; Chronic Pain; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid;	2013
Perioperative gabapentinoids: choice of agent, dose, timing, and effects on chronic postsurgical pain. Anesthesiology, 2013, Volume: 119, Issue:5 Topics: Amines; Analgesics; Chronic Pain; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid;	2013
Perioperative gabapentinoids: choice of agent, dose, timing, and effects on chronic postsurgical pain. Anesthesiology, 2013, Volume: 119, Issue:5 Topics: Amines; Analgesics; Chronic Pain; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid;	2013
Perioperative gabapentinoids: choice of agent, dose, timing, and effects on chronic postsurgical pain. Anesthesiology, 2013, Volume: 119, Issue:5 Topics: Amines; Analgesics; Chronic Pain; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid;	2013
Perioperative gabapentinoids: choice of agent, dose, timing, and effects on chronic postsurgical pain. Anesthesiology, 2013, Volume: 119, Issue:5 Topics: Amines; Analgesics; Chronic Pain; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid;	2013
Perioperative gabapentinoids: choice of agent, dose, timing, and effects on chronic postsurgical pain. Anesthesiology, 2013, Volume: 119, Issue:5 Topics: Amines; Analgesics; Chronic Pain; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid;	2013
Perioperative gabapentinoids: choice of agent, dose, timing, and effects on chronic postsurgical pain. Anesthesiology, 2013, Volume: 119, Issue:5 Topics: Amines; Analgesics; Chronic Pain; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid;	2013
Perioperative gabapentinoids: choice of agent, dose, timing, and effects on chronic postsurgical pain. Anesthesiology, 2013, Volume: 119, Issue:5 Topics: Amines; Analgesics; Chronic Pain; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid;	2013
Perioperative gabapentinoids: choice of agent, dose, timing, and effects on chronic postsurgical pain. Anesthesiology, 2013, Volume: 119, Issue:5 Topics: Amines; Analgesics; Chronic Pain; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid;	2013
Post-surgical pain syndromes: a review for the non-pain specialist. Canadian journal of anaesthesia = Journal canadien d'anesthesie, 2014, Volume: 61, Issue:2 Topics: Age Factors; Amines; Analgesics; Anesthesia; Anesthetics; Anesthetics, Local; Animals; Chronic Pain;	2014
Non-surgical interventions for the management of chronic pelvic pain. The Cochrane database of systematic reviews, 2014, Mar-05, Issue:3 Topics: Amines; Amitriptyline; Analgesics; Chronic Pain; Clonidine; Contraceptive Agents, Female; Cyclohexan	2014
Gabapentin for chronic neuropathic pain and fibromyalgia in adults. The Cochrane database of systematic reviews, 2014, Apr-27, Issue:4 Topics: Adult; Amines; Analgesics; Chronic Disease; Chronic Pain; Cyclohexanecarboxylic Acids; Fibromyalgia;	2014
Impact of pregabalin on acute and persistent postoperative pain: a systematic review and meta-analysis. British journal of anaesthesia, 2015, Volume: 114, Issue:1 Topics: Acute Pain; Analgesics; Chronic Pain; gamma-Aminobutyric Acid; Humans; Pain, Postoperative; Pregabal	2015
Impact of pregabalin on acute and persistent postoperative pain: a systematic review and meta-analysis. British journal of anaesthesia, 2015, Volume: 114, Issue:1 Topics: Acute Pain; Analgesics; Chronic Pain; gamma-Aminobutyric Acid; Humans; Pain, Postoperative; Pregabal	2015
Impact of pregabalin on acute and persistent postoperative pain: a systematic review and meta-analysis. British journal of anaesthesia, 2015, Volume: 114, Issue:1 Topics: Acute Pain; Analgesics; Chronic Pain; gamma-Aminobutyric Acid; Humans; Pain, Postoperative; Pregabal	2015
Impact of pregabalin on acute and persistent postoperative pain: a systematic review and meta-analysis. British journal of anaesthesia, 2015, Volume: 114, Issue:1 Topics: Acute Pain; Analgesics; Chronic Pain; gamma-Aminobutyric Acid; Humans; Pain, Postoperative; Pregabal	2015
Impact of pregabalin on acute and persistent postoperative pain: a systematic review and meta-analysis. British journal of anaesthesia, 2015, Volume: 114, Issue:1 Topics: Acute Pain; Analgesics; Chronic Pain; gamma-Aminobutyric Acid; Humans; Pain, Postoperative; Pregabal	2015
Impact of pregabalin on acute and persistent postoperative pain: a systematic review and meta-analysis. British journal of anaesthesia, 2015, Volume: 114, Issue:1 Topics: Acute Pain; Analgesics; Chronic Pain; gamma-Aminobutyric Acid; Humans; Pain, Postoperative; Pregabal	2015
Impact of pregabalin on acute and persistent postoperative pain: a systematic review and meta-analysis. British journal of anaesthesia, 2015, Volume: 114, Issue:1 Topics: Acute Pain; Analgesics; Chronic Pain; gamma-Aminobutyric Acid; Humans; Pain, Postoperative; Pregabal	2015
Impact of pregabalin on acute and persistent postoperative pain: a systematic review and meta-analysis. British journal of anaesthesia, 2015, Volume: 114, Issue:1 Topics: Acute Pain; Analgesics; Chronic Pain; gamma-Aminobutyric Acid; Humans; Pain, Postoperative; Pregabal	2015
Impact of pregabalin on acute and persistent postoperative pain: a systematic review and meta-analysis. British journal of anaesthesia, 2015, Volume: 114, Issue:1 Topics: Acute Pain; Analgesics; Chronic Pain; gamma-Aminobutyric Acid; Humans; Pain, Postoperative; Pregabal	2015
Impact of pregabalin on acute and persistent postoperative pain: a systematic review and meta-analysis. British journal of anaesthesia, 2015, Volume: 114, Issue:1 Topics: Acute Pain; Analgesics; Chronic Pain; gamma-Aminobutyric Acid; Humans; Pain, Postoperative; Pregabal	2015
Impact of pregabalin on acute and persistent postoperative pain: a systematic review and meta-analysis. British journal of anaesthesia, 2015, Volume: 114, Issue:1 Topics: Acute Pain; Analgesics; Chronic Pain; gamma-Aminobutyric Acid; Humans; Pain, Postoperative; Pregabal	2015
Impact of pregabalin on acute and persistent postoperative pain: a systematic review and meta-analysis. British journal of anaesthesia, 2015, Volume: 114, Issue:1 Topics: Acute Pain; Analgesics; Chronic Pain; gamma-Aminobutyric Acid; Humans; Pain, Postoperative; Pregabal	2015
Impact of pregabalin on acute and persistent postoperative pain: a systematic review and meta-analysis. British journal of anaesthesia, 2015, Volume: 114, Issue:1 Topics: Acute Pain; Analgesics; Chronic Pain; gamma-Aminobutyric Acid; Humans; Pain, Postoperative; Pregabal	2015
Impact of pregabalin on acute and persistent postoperative pain: a systematic review and meta-analysis. British journal of anaesthesia, 2015, Volume: 114, Issue:1 Topics: Acute Pain; Analgesics; Chronic Pain; gamma-Aminobutyric Acid; Humans; Pain, Postoperative; Pregabal	2015
Impact of pregabalin on acute and persistent postoperative pain: a systematic review and meta-analysis. British journal of anaesthesia, 2015, Volume: 114, Issue:1 Topics: Acute Pain; Analgesics; Chronic Pain; gamma-Aminobutyric Acid; Humans; Pain, Postoperative; Pregabal	2015
Impact of pregabalin on acute and persistent postoperative pain: a systematic review and meta-analysis. British journal of anaesthesia, 2015, Volume: 114, Issue:1 Topics: Acute Pain; Analgesics; Chronic Pain; gamma-Aminobutyric Acid; Humans; Pain, Postoperative; Pregabal	2015
Biogenic Amines and the Amino Acids GABA and Glutamate: Relationships with Pain and Depression. Modern trends in pharmacopsychiatry, 2015, Volume: 30 Topics: Biogenic Amines; Chronic Pain; Depressive Disorder; gamma-Aminobutyric Acid; Glutamic Acid; Humans	2015
From pulses to pain relief: an update on the mechanisms of rTMS-induced analgesic effects. European journal of pain (London, England), 2016, Volume: 20, Issue:5 Topics: Brain; Chronic Pain; Dopamine; gamma-Aminobutyric Acid; Humans; Long-Term Potentiation; Motor Cortex	2016
Preventing chronic postoperative pain. Anaesthesia, 2016, Volume: 71 Suppl 1 Topics: Amines; Analgesics; Chronic Pain; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid;	2016
Combined approaches for the relief of spinal cord injury-induced neuropathic pain. Complementary therapies in medicine, 2016, Volume: 25 Topics: Acupuncture Therapy; Chronic Pain; gamma-Aminobutyric Acid; Humans; Neuralgia; Pain Management; Spin	2016
Can Chronic Pain Be Prevented? Anesthesiology clinics, 2016, Volume: 34, Issue:2 Topics: Acute Pain; Amines; Anesthesia, Conduction; Chronic Pain; Cyclohexanecarboxylic Acids; Epigenesis, G	2016
An update of management of insomnia in patients with chronic orofacial pain. Oral diseases, 2017, Volume: 23, Issue:8 Topics: Amines; Anticonvulsants; Antidepressive Agents; Benzodiazepines; Chronic Pain; Cognitive Behavioral	2017
Neonatal pain management. Seminars in perinatology, 2017, Volume: 41, Issue:2 Topics: Amines; Analgesics, Opioid; Anti-Anxiety Agents; Barbiturates; Chronic Pain; Cyclohexanecarboxylic A	2017
Gabapentinoids for chronic low back pain: a protocol for systematic review and meta-analysis of randomised controlled trials. BMJ open, 2016, 11-10, Volume: 6, Issue:11 Topics: Amines; Chronic Pain; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Low	2016
Pharmacotherapy of fibromyalgia. Best practice & research. Clinical rheumatology, 2011, Volume: 25, Issue:2 Topics: Analgesics; Chronic Pain; Clinical Trials as Topic; Cognition Disorders; Cyclopropanes; Duloxetine H	2011
Fibromyalgia and sleep. Best practice & research. Clinical rheumatology, 2011, Volume: 25, Issue:2 Topics: Analgesics; Central Nervous System Sensitization; Chronic Pain; Cyclopropanes; Duloxetine Hydrochlor	2011
Spinal cord stimulation: neurophysiological and neurochemical mechanisms of action. Current pain and headache reports, 2012, Volume: 16, Issue:3 Topics: Animals; Chronic Pain; Electric Stimulation Therapy; gamma-Aminobutyric Acid; Mice; Mice, Transgenic	2012
The prevention of chronic postsurgical pain using gabapentin and pregabalin: a combined systematic review and meta-analysis. Anesthesia and analgesia, 2012, Volume: 115, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Chronic Pain; Cyclohexanecarboxylic	2012
The prevention of chronic postsurgical pain using gabapentin and pregabalin: a combined systematic review and meta-analysis. Anesthesia and analgesia, 2012, Volume: 115, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Chronic Pain; Cyclohexanecarboxylic	2012
The prevention of chronic postsurgical pain using gabapentin and pregabalin: a combined systematic review and meta-analysis. Anesthesia and analgesia, 2012, Volume: 115, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Chronic Pain; Cyclohexanecarboxylic	2012
The prevention of chronic postsurgical pain using gabapentin and pregabalin: a combined systematic review and meta-analysis. Anesthesia and analgesia, 2012, Volume: 115, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Chronic Pain; Cyclohexanecarboxylic	2012
Imaging central neurochemical alterations in chronic pain with proton magnetic resonance spectroscopy. Neuroscience letters, 2012, Jun-29, Volume: 520, Issue:2 Topics: Analgesics; Brain; Chronic Pain; Drug Discovery; gamma-Aminobutyric Acid; Glutamic Acid; Glutamine;	2012
[Mechanisms of action of therapeutic agents in the treatment of chronic pain in the spinal cord]. Masui. The Japanese journal of anesthesiology, 2011, Volume: 60 Suppl Topics: Amines; Antidepressive Agents; Calcium Channel Blockers; Chronic Pain; Cyclohexanecarboxylic Acids;	2011

Article	Year
GaPP2, a multicentre randomised controlled trial of the efficacy of gabapentin for the management of chronic pelvic pain in women: study protocol. BMJ open, 2018, 01-31, Volume: 8, Issue:1 Topics: Adolescent; Adult; Amines; Analgesics; Chronic Disease; Chronic Pain; Cyclohexanecarboxylic Acids; D	2018
Spinal cord stimulation modulates cerebral neurobiology: a proton magnetic resonance spectroscopy study. Neuroradiology, 2013, Volume: 55, Issue:8 Topics: Aged; Chronic Pain; Cohort Studies; Female; gamma-Aminobutyric Acid; Glucose; Humans; Magnetic Reson	2013
Spinal cord stimulation modulates cerebral neurobiology: a proton magnetic resonance spectroscopy study. Neuroradiology, 2013, Volume: 55, Issue:8 Topics: Aged; Chronic Pain; Cohort Studies; Female; gamma-Aminobutyric Acid; Glucose; Humans; Magnetic Reson	2013
Spinal cord stimulation modulates cerebral neurobiology: a proton magnetic resonance spectroscopy study. Neuroradiology, 2013, Volume: 55, Issue:8 Topics: Aged; Chronic Pain; Cohort Studies; Female; gamma-Aminobutyric Acid; Glucose; Humans; Magnetic Reson	2013
Spinal cord stimulation modulates cerebral neurobiology: a proton magnetic resonance spectroscopy study. Neuroradiology, 2013, Volume: 55, Issue:8 Topics: Aged; Chronic Pain; Cohort Studies; Female; gamma-Aminobutyric Acid; Glucose; Humans; Magnetic Reson	2013
Spinal cord stimulation modulates cerebral neurobiology: a proton magnetic resonance spectroscopy study. Neuroradiology, 2013, Volume: 55, Issue:8 Topics: Aged; Chronic Pain; Cohort Studies; Female; gamma-Aminobutyric Acid; Glucose; Humans; Magnetic Reson	2013
Spinal cord stimulation modulates cerebral neurobiology: a proton magnetic resonance spectroscopy study. Neuroradiology, 2013, Volume: 55, Issue:8 Topics: Aged; Chronic Pain; Cohort Studies; Female; gamma-Aminobutyric Acid; Glucose; Humans; Magnetic Reson	2013
Spinal cord stimulation modulates cerebral neurobiology: a proton magnetic resonance spectroscopy study. Neuroradiology, 2013, Volume: 55, Issue:8 Topics: Aged; Chronic Pain; Cohort Studies; Female; gamma-Aminobutyric Acid; Glucose; Humans; Magnetic Reson	2013
Spinal cord stimulation modulates cerebral neurobiology: a proton magnetic resonance spectroscopy study. Neuroradiology, 2013, Volume: 55, Issue:8 Topics: Aged; Chronic Pain; Cohort Studies; Female; gamma-Aminobutyric Acid; Glucose; Humans; Magnetic Reson	2013
Spinal cord stimulation modulates cerebral neurobiology: a proton magnetic resonance spectroscopy study. Neuroradiology, 2013, Volume: 55, Issue:8 Topics: Aged; Chronic Pain; Cohort Studies; Female; gamma-Aminobutyric Acid; Glucose; Humans; Magnetic Reson	2013
Intrathecal gabapentin to treat chronic intractable noncancer pain. Anesthesiology, 2013, Volume: 119, Issue:3 Topics: Adult; Aged; Amines; Analgesics; Chronic Pain; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm	2013
Pregabalin rectifies aberrant brain chemistry, connectivity, and functional response in chronic pain patients. Anesthesiology, 2013, Volume: 119, Issue:6 Topics: Adolescent; Adult; Aged; Analgesics; Brain Chemistry; Chronic Pain; Cross-Over Studies; Double-Blind	2013
A randomized controlled trial of gabapentin for chronic low back pain with and without a radiating component. Pain, 2016, Volume: 157, Issue:7 Topics: Adult; Aged; Amines; Analgesics; Chronic Pain; Cyclohexanecarboxylic Acids; Disability Evaluation; D	2016
Gabapentin for the Management of Chronic Pelvic Pain in Women (GaPP1): A Pilot Randomised Controlled Trial. PloS one, 2016, Volume: 11, Issue:4 Topics: Adolescent; Adult; Amines; Analgesics; Chronic Pain; Cost-Benefit Analysis; Cyclohexanecarboxylic Ac	2016
Phantom motor execution facilitated by machine learning and augmented reality as treatment for phantom limb pain: a single group, clinical trial in patients with chronic intractable phantom limb pain. Lancet (London, England), 2016, 12-10, Volume: 388, Issue:10062 Topics: Adult; Aged; Amines; Amputation, Surgical; Chronic Pain; Cyclohexanecarboxylic Acids; Exercise Thera	2016
Phantom motor execution facilitated by machine learning and augmented reality as treatment for phantom limb pain: a single group, clinical trial in patients with chronic intractable phantom limb pain. Lancet (London, England), 2016, 12-10, Volume: 388, Issue:10062 Topics: Adult; Aged; Amines; Amputation, Surgical; Chronic Pain; Cyclohexanecarboxylic Acids; Exercise Thera	2016
Phantom motor execution facilitated by machine learning and augmented reality as treatment for phantom limb pain: a single group, clinical trial in patients with chronic intractable phantom limb pain. Lancet (London, England), 2016, 12-10, Volume: 388, Issue:10062 Topics: Adult; Aged; Amines; Amputation, Surgical; Chronic Pain; Cyclohexanecarboxylic Acids; Exercise Thera	2016
Phantom motor execution facilitated by machine learning and augmented reality as treatment for phantom limb pain: a single group, clinical trial in patients with chronic intractable phantom limb pain. Lancet (London, England), 2016, 12-10, Volume: 388, Issue:10062 Topics: Adult; Aged; Amines; Amputation, Surgical; Chronic Pain; Cyclohexanecarboxylic Acids; Exercise Thera	2016
Phantom motor execution facilitated by machine learning and augmented reality as treatment for phantom limb pain: a single group, clinical trial in patients with chronic intractable phantom limb pain. Lancet (London, England), 2016, 12-10, Volume: 388, Issue:10062 Topics: Adult; Aged; Amines; Amputation, Surgical; Chronic Pain; Cyclohexanecarboxylic Acids; Exercise Thera	2016
Phantom motor execution facilitated by machine learning and augmented reality as treatment for phantom limb pain: a single group, clinical trial in patients with chronic intractable phantom limb pain. Lancet (London, England), 2016, 12-10, Volume: 388, Issue:10062 Topics: Adult; Aged; Amines; Amputation, Surgical; Chronic Pain; Cyclohexanecarboxylic Acids; Exercise Thera	2016
Phantom motor execution facilitated by machine learning and augmented reality as treatment for phantom limb pain: a single group, clinical trial in patients with chronic intractable phantom limb pain. Lancet (London, England), 2016, 12-10, Volume: 388, Issue:10062 Topics: Adult; Aged; Amines; Amputation, Surgical; Chronic Pain; Cyclohexanecarboxylic Acids; Exercise Thera	2016
Phantom motor execution facilitated by machine learning and augmented reality as treatment for phantom limb pain: a single group, clinical trial in patients with chronic intractable phantom limb pain. Lancet (London, England), 2016, 12-10, Volume: 388, Issue:10062 Topics: Adult; Aged; Amines; Amputation, Surgical; Chronic Pain; Cyclohexanecarboxylic Acids; Exercise Thera	2016
Phantom motor execution facilitated by machine learning and augmented reality as treatment for phantom limb pain: a single group, clinical trial in patients with chronic intractable phantom limb pain. Lancet (London, England), 2016, 12-10, Volume: 388, Issue:10062 Topics: Adult; Aged; Amines; Amputation, Surgical; Chronic Pain; Cyclohexanecarboxylic Acids; Exercise Thera	2016
Phantom motor execution facilitated by machine learning and augmented reality as treatment for phantom limb pain: a single group, clinical trial in patients with chronic intractable phantom limb pain. Lancet (London, England), 2016, 12-10, Volume: 388, Issue:10062 Topics: Adult; Aged; Amines; Amputation, Surgical; Chronic Pain; Cyclohexanecarboxylic Acids; Exercise Thera	2016
Phantom motor execution facilitated by machine learning and augmented reality as treatment for phantom limb pain: a single group, clinical trial in patients with chronic intractable phantom limb pain. Lancet (London, England), 2016, 12-10, Volume: 388, Issue:10062 Topics: Adult; Aged; Amines; Amputation, Surgical; Chronic Pain; Cyclohexanecarboxylic Acids; Exercise Thera	2016
Phantom motor execution facilitated by machine learning and augmented reality as treatment for phantom limb pain: a single group, clinical trial in patients with chronic intractable phantom limb pain. Lancet (London, England), 2016, 12-10, Volume: 388, Issue:10062 Topics: Adult; Aged; Amines; Amputation, Surgical; Chronic Pain; Cyclohexanecarboxylic Acids; Exercise Thera	2016
Phantom motor execution facilitated by machine learning and augmented reality as treatment for phantom limb pain: a single group, clinical trial in patients with chronic intractable phantom limb pain. Lancet (London, England), 2016, 12-10, Volume: 388, Issue:10062 Topics: Adult; Aged; Amines; Amputation, Surgical; Chronic Pain; Cyclohexanecarboxylic Acids; Exercise Thera	2016
Phantom motor execution facilitated by machine learning and augmented reality as treatment for phantom limb pain: a single group, clinical trial in patients with chronic intractable phantom limb pain. Lancet (London, England), 2016, 12-10, Volume: 388, Issue:10062 Topics: Adult; Aged; Amines; Amputation, Surgical; Chronic Pain; Cyclohexanecarboxylic Acids; Exercise Thera	2016
Phantom motor execution facilitated by machine learning and augmented reality as treatment for phantom limb pain: a single group, clinical trial in patients with chronic intractable phantom limb pain. Lancet (London, England), 2016, 12-10, Volume: 388, Issue:10062 Topics: Adult; Aged; Amines; Amputation, Surgical; Chronic Pain; Cyclohexanecarboxylic Acids; Exercise Thera	2016
Phantom motor execution facilitated by machine learning and augmented reality as treatment for phantom limb pain: a single group, clinical trial in patients with chronic intractable phantom limb pain. Lancet (London, England), 2016, 12-10, Volume: 388, Issue:10062 Topics: Adult; Aged; Amines; Amputation, Surgical; Chronic Pain; Cyclohexanecarboxylic Acids; Exercise Thera	2016
Phantom motor execution facilitated by machine learning and augmented reality as treatment for phantom limb pain: a single group, clinical trial in patients with chronic intractable phantom limb pain. Lancet (London, England), 2016, 12-10, Volume: 388, Issue:10062 Topics: Adult; Aged; Amines; Amputation, Surgical; Chronic Pain; Cyclohexanecarboxylic Acids; Exercise Thera	2016
Phantom motor execution facilitated by machine learning and augmented reality as treatment for phantom limb pain: a single group, clinical trial in patients with chronic intractable phantom limb pain. Lancet (London, England), 2016, 12-10, Volume: 388, Issue:10062 Topics: Adult; Aged; Amines; Amputation, Surgical; Chronic Pain; Cyclohexanecarboxylic Acids; Exercise Thera	2016
Phantom motor execution facilitated by machine learning and augmented reality as treatment for phantom limb pain: a single group, clinical trial in patients with chronic intractable phantom limb pain. Lancet (London, England), 2016, 12-10, Volume: 388, Issue:10062 Topics: Adult; Aged; Amines; Amputation, Surgical; Chronic Pain; Cyclohexanecarboxylic Acids; Exercise Thera	2016
Phantom motor execution facilitated by machine learning and augmented reality as treatment for phantom limb pain: a single group, clinical trial in patients with chronic intractable phantom limb pain. Lancet (London, England), 2016, 12-10, Volume: 388, Issue:10062 Topics: Adult; Aged; Amines; Amputation, Surgical; Chronic Pain; Cyclohexanecarboxylic Acids; Exercise Thera	2016
Phantom motor execution facilitated by machine learning and augmented reality as treatment for phantom limb pain: a single group, clinical trial in patients with chronic intractable phantom limb pain. Lancet (London, England), 2016, 12-10, Volume: 388, Issue:10062 Topics: Adult; Aged; Amines; Amputation, Surgical; Chronic Pain; Cyclohexanecarboxylic Acids; Exercise Thera	2016
Phantom motor execution facilitated by machine learning and augmented reality as treatment for phantom limb pain: a single group, clinical trial in patients with chronic intractable phantom limb pain. Lancet (London, England), 2016, 12-10, Volume: 388, Issue:10062 Topics: Adult; Aged; Amines; Amputation, Surgical; Chronic Pain; Cyclohexanecarboxylic Acids; Exercise Thera	2016
Phantom motor execution facilitated by machine learning and augmented reality as treatment for phantom limb pain: a single group, clinical trial in patients with chronic intractable phantom limb pain. Lancet (London, England), 2016, 12-10, Volume: 388, Issue:10062 Topics: Adult; Aged; Amines; Amputation, Surgical; Chronic Pain; Cyclohexanecarboxylic Acids; Exercise Thera	2016
Phantom motor execution facilitated by machine learning and augmented reality as treatment for phantom limb pain: a single group, clinical trial in patients with chronic intractable phantom limb pain. Lancet (London, England), 2016, 12-10, Volume: 388, Issue:10062 Topics: Adult; Aged; Amines; Amputation, Surgical; Chronic Pain; Cyclohexanecarboxylic Acids; Exercise Thera	2016
Phantom motor execution facilitated by machine learning and augmented reality as treatment for phantom limb pain: a single group, clinical trial in patients with chronic intractable phantom limb pain. Lancet (London, England), 2016, 12-10, Volume: 388, Issue:10062 Topics: Adult; Aged; Amines; Amputation, Surgical; Chronic Pain; Cyclohexanecarboxylic Acids; Exercise Thera	2016
The effects of gabapentin on acute and chronic postoperative pain after coronary artery bypass graft surgery. Journal of cardiothoracic and vascular anesthesia, 2011, Volume: 25, Issue:5 Topics: Acute Disease; Aged; Amines; Analgesics; Analgesics, Opioid; Chronic Disease; Chronic Pain; Coronary	2011
The analgesic effect of pregabalin in patients with chronic pain is reflected by changes in pharmaco-EEG spectral indices. British journal of clinical pharmacology, 2012, Volume: 73, Issue:3 Topics: Adult; Analgesics; Chronic Pain; Dose-Response Relationship, Drug; Double-Blind Method; Electroencep	2012
Pregabalin for the treatment of abdominal adhesion pain: a randomized, double-blind, placebo-controlled trial. American journal of therapeutics, 2012, Volume: 19, Issue:6 Topics: Abdomen; Abdominal Pain; Adult; Analgesics; Chronic Pain; Double-Blind Method; Female; gamma-Aminobu	2012
Chronic postthoracotomy pain and health-related quality of life. The Annals of thoracic surgery, 2012, Volume: 93, Issue:4 Topics: Aged; Amines; Analgesics; Chronic Pain; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Fo	2012
Perioperative pregabalin for acute and chronic pain after abdominal hysterectomy or myomectomy: a randomised controlled trial. European journal of anaesthesiology, 2012, Volume: 29, Issue:11 Topics: Acetaminophen; Acute Pain; Adult; Analgesics; Chronic Pain; Codeine; Double-Blind Method; Drug Combi	2012